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Background
Personal experience and a growing body of empirical studies (initi-
ated by Gerd Gigerenzer) show that people generally find it hard to
understand statistical measures of test accuracy. Sensitivity and spe-
cificity are technically useful for comparing assay performance be-
cause they are (mathematically at least) independent of study design
and disease prevalence. For patients and clinicians, the clinically im-
portant measures for decision-making are predictive values and their
relation to decision thresholds that depend on the personal values
(positive and negative) placed on outcomes.
Objectives
To help people develop an intuitive understanding of diagnostic ac-
curacy measures and their technical and clinical application.
Methods
We introduce the concepts of technical accuracy (sensitivity and spe-
cificity) and clinical accuracy (predictive values) to distinguish be-
tween the two main applications of test performance measures, and
to be used alongside the concept of clinical utility.
We developed two free interactive tools using the RStudio applica-
tion “Shiny” that allow users to quantitatively and visually explore
the effects on technical and clinical accuracy of true and false test re-
sults and prevalence.
https://micncltools.shinyapps.io/TestAccuracy/
https://micncltools.shinyapps.io/ClinicalAccuracyAndUtility/
Both tools also show the effects of study sample size on uncertainties
in test performance measures. The clinical accuracy tool visualises
pre-test and post-test probabilities of disease in relation to clinical
decision thresholds for positive and negative test results.© The Author(s). 2018 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeResults
Using a point of care test for Clostridium difficile, we demonstrate the
effect of prevalence and distinct clinical scenarios on the clinical ac-
curacy and utility of the test in the UK NHS.
Conclusions
These tools may be useful for developers of clinical tests, authors of
test evaluation reports, and clinicians and patients for interpreting
and applying test results.
Future developments should include tools to help people quantify
their utilities for the outcomes resulting from acting/not acting on
test results, and determine what their decision thresholds are.
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(requiring delivery <34 weeks’ gestation) may improve maternal and
infant health outcomes by identifying women who will benefit from
management such as aspirin prophylaxis. Risk models using routinely
measured factors are needed in settings where specialised tests are
not available. However, few such models have been externally
validated.
Objective: To assess the performance of the Baschat (2014) [1] risk
model that incorporates history of chronic hypertension, diabetes
and mean arterial pressure (MAP) to predict early-onset pre-
eclampsia in early pregnancy using the Perinatal Antiplatelet Review
of International Studies (PARIS) randomised controlled trial dataset.
Methods: A retrospective individual-participant data meta-analysis to
validate the Baschat model (reported sensitivity 55%/66% at 10%/
20% false positive rates (FPRs) respectively, area-under-curve (AUC)
0.83). Trials were eligible if they did not select women based on the
presence/absence of high-risk factors; enrolled women <28 weeks’
gestation; and reported model predictors and pre-eclampsia. Women
assigned to the control arm were included. Model performance was
assessed by estimating sensitivity, specificity, positive (PPV) and
negative (NPV) predictive value for predicting early-onset pre-
eclampsia at: (i) 0.7% risk threshold to classify low- versus high-risk;
and (ii) 10%/20% FPRs as reported in the original publication. The
AUC and 95% confidence interval (CI) was calculated. Model calibra-
tion was assessed using the Hosmer and Lemeshow goodness-of-fit
test and a calibration plot.
Results: Three eligible trials included 4510 women. Pre-eclampsia
prevalence was 4.9%. For prediction of early-onset pre-eclampsia
(n=25, 0.6%), model sensitivity was 28.0% (95% CI 14.3-47.6%), speci-
ficity 84.3% (83.2-85.3%), PPV 1.0% (0.5%-2.0%), NPV 99.5% (99.3-
99.7%). At 10% and 20% FPRs, sensitivity was 20.0% (8.9-39.1%) and
32.0% (17.2-51.6%) respectively; AUC=0.55 (0.43-0.68), goodness-of-fit
p=0.86.
Conclusion:
Model performance for predicting early-onset pre-eclampsia was
poor in this validation population. Determining appropriate risk
thresholds for assessment of clinical performance will be important
for ongoing model development.
Reference
1. Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG.
Prediction of preeclampsia utilizing the first trimester screening
examination. American Journal of Obstetrics & Gynecology. 2014 Nov
1;211(5):514-e1.P4
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Background: Systematic reviews in prognosis can become unman-
ageable due to large numbers of predictors, many of which are con-
sidered by very few individual studies.
However, a “rule of thumb” excluding predictors only found in
few studies can risk excluding clinically important predictors.Methods are needed to select those that are worthwhile for
review.
Objectives: To describe methods used to select biomarkers for inclu-
sion in a systematic review of prognostic factors for severe Crohn’s
disease.
Methods: To manage the potentially large number of candidate pre-
dictors, we first subdivided the full review into four separate bio-
marker areas: (1) serological; (2) clinical; (3) genetic and; (4)
combinations of tests/biomarkers.
Only biomarkers reported in five or more primary studies were
included automatically, with the remainder reviewed by a panel
of gastroenterologists to identify those believed to be “promis-
ing” despite being reported in few studies. We stipulated a priori
that only five such “promising” biomarkers would be included
across all reviews.
The panel was blinded to how many and which studies had consid-
ered each biomarker. Each member ranked their top five across all
biomarker areas, with the top scoring biomarkers then being eligible.
Results: Overall 169 candidate predictors were identified, 32 were in-
cluded and 137 were excluded.
The panel selected one additional biomarker each for the serological
(CRP) and genetic reviews (FOX03A), while three were selected for
the clinical review (severe endoscopic lesions, stricturing disease and
response to therapy) in addition to those which were automatically
eligible.
Conclusion: Our approach eliminated a large volume of biomarkers
with insufficient evidence to be clinically useful, and which were not
considered promising by our panel.
Reference to expert opinion ensured the review did not exclude im-
portant or newer biomarkers while simultaneously minimising inclu-
sion of results that have not been well evaluated in the literature.P5
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Background: Tissue oxygenation is essential in critically ill patients,
but is difficult to measure at the cellular level. The protoporphyrin IX-
triple state lifetime technique, measuring mitochondrial oxygenation
tension (mitoPO2) in vivo, may be a new monitor to measure oxygen-
ation the cellular level. The measurements are obtained through the
oxygen-dependent optical properties of protoporphyrin IX.
Objective: To determine the feasibility and variability of mitoPO2
measurement in critically ill patients with anaemia.
Methods: We prospectively included 20 critically ill patients ad-
mitted to the Intensive Care of the Leiden University Medical
Center with anaemia scheduled to receive a red cell transfusion.
We assessed mitoPO2 on the anterior chest wall at multiple
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 3 of 44time points, before and after red cell transfusion. MitoPO2 mea-
surements were performed using a COMET monitor (Photonics
Healthcare, Utrecht, The Netherlands) on skin primed during 4
hours with an ALA containing patch (Alacare, Photonamic, We-
del, Germany) for induction of mitochondrial PpIX. Reported
values are a mean mitoPO2 of 5 consecutive measures at each
time point.
Results: A mitoPO2 measurement was obtained in all but 1 par-
ticipant, most likely due to excessive chlorhexidin at the meas-
urement site. All measurements were above the signal-to-noise
ratio of 25, irrespective of severity of critical illness assessed via
APACHE IV score (range 49-171). The median and interquartile
ranges of mitoPO2 before and after transfusion were 66.9
mmHg (IQR 61.5-77.7 mmHg), and 65.8 mmHg (IQR 57.5-87.2)
mmHg, respectively. Median within-subject variability was lim-
ited during the first 3 hours after transfusion (3.96 (IQR 2.1-
11.4)mmHg), but increased considerably after 24 hours (7.9 (IQR
4.3-13.9) mmHg).
Conclusion: It is feasible to measure mitochondrial oxygen tension in
critically ill patients. The measurements seem to be most reliable in
the first 3 hours after patch removal. Interestingly, mitoPO2 values in
our study population were higher than those previously reported in
healthy volunteers.P6
The area between curves, a non-parametric method to evaluate a
biomarker for patient treatment selection
Y. Blangero1,2, M. Rabilloud1,2, F. Subtil1,2
1Service de Biostatistique-Bioinformatique, Hospices Civils de Lyon, Lyon,
France; 2Univ Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et
Biologie Évolutive UMR 5558, Villeurbanne, France
Correspondence: Y. Blangero
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P6
Background: Biological markers able to predict the benefit of a
given treatment vs. another one are essential in precision
medicine. Classically, a predictive marker is detected through
testing a marker- by-treatment interaction in a parametric re-
gression model, and most of the other methods rely on model-
ling the risk of event occurrence under each treatment arm. All
these methods make assumptions that may be difficult to
check.
Objectives: A simple approach, which does not make any parametric
assumption, is proposed to detect and assess the overall predictive
ability of a quantitative marker in clinical trials.
Methods: This approach is a non-parametric and graphical
method that relies on the area between each treatment-arm-
specific ROC curve (ABC) as an indicator of the predictive ability
of the maker. The approach is justified by the relationship be-
tween ROC curves and risk curves, the latter being key tools in
assessing predictive markers.
Results: A simulation study was conducted to assess the ABC es-
timation method and compare it with two approaches based on
risk modelling: the Total Gain approach (TG) and the interaction
approach. The simulations showed that the ABC estimate has a
low relative bias and that its confidence interval has a good
coverage probability. The mean relative bias in the ABC is at
least as low as in the TG in almost all combinations of sample
size, ABC, and risk. The power of the ABC estimation method
was close to that of the interaction coefficient. The method was
applied to PETACC-8 trial data on the use of FOLFOX4 vs. FOL-
FOX4 + cetuximab in stage III colon adenocarcinoma. It enabled
detecting a predictive marker: the DDR2 gene amplification
level.Conclusion: The ABC is a simple indicator that may be recom-
mended as a first step in the identification and overall assessment of
a predictive marker.P7
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Background
Accurate prediction of preterm delivery remains notoriously challen-
ging. It would enable targeted interventions and reduce unnecessary
hospital admissions and transfers. Quantitative fetal fibronectin
(qfFN) is a new bedside test to improve diagnosis of preterm labour.
Objectives
To evaluate the accuracy of qfFN to rule out spontaneous pre-
term delivery within seven days, and to develop and internally
validate a decision support tool for the management of symp-
tomatic women.
Methods
We performed an IPD meta-analysis of 5 European studies of
symptomatic women at 22+0-34+6 weeks gestation. We used
qfFN and clinical risk factors from a pre-defined set of predic-
tors. We used multivariable logistic regression firstly with all
predictors, and secondly with backward stepwise selection
(threshold of p-value<0.1) to develop a prognostic model to
predict preterm delivery within seven days. Multiple imputation
was used for predictor values considered missing at random,
and non-linear trends allowed for continuous predictors. Cluster-
ing and between-study heterogeneity of outcome incidence was
taken into account by a separate intercept term per study. The
performance of the model was assessed by overall fit (Nagelk-
erke R2), discrimination (AUC). Bootstrap re-sampling techniques
were used for internal validation and optimism-adjustment
using shrinkage.
Results
We included 1783 women, with 139(7.8%) events of preterm de-
livery within seven days. Table 1 shows the prognostic model
before and after variable selection. For the latter, besides qfFN,
the model included smoking, ethnicity, nulliparity and multiple
pregnancy. After applying a uniform shrinkage factor of 0.92,
the model showed an R2 of 0.39 and an AUC of 0.89 (95% CI
0.87-0.93).
Conclusion
A prognostic model including qfFN and clinical risk factors
showed excellent performance in the prediction of preterm deliv-
ery. As part of the QUIDS study, the model (including choice of
intercept) will be externally validated using data from a prospect-
ive cohort study in 26 UK sites.
Table 1 (abstract P7). Multivariable models (before and after variable
selection) for predicting spontaneous preterm delivery within seven
days in symptomatic women
Model including
all variables
Model after variable
selection
Beta OR (95% CI) Betaa OR (95% CI)
Intercept
Study 1 -7.9 -4.6
Study 2 -8.5 -5.3
Study 3 -9.0 -5.7
Study 4 -8.7 -5.4
Study 5 -9.3 -6.0
Quantitative fetal fibronectin (qfFN)b
(qfFN+1)/100)^0.5 2.0 7.6 (5.7 – 10) 1.89 6.6 (4.9 – 8.9)
Age (yr) 0.02 1.0 (0.98 – 1.1) - -
BMI (kg/m2) 0.02 1.0 (0.96 – 1.1) - -
Smoking -0.66 0.52 (0.24 –
1.1)
-0.67 0.51 (0.24 –
1.08)
Ethnicity
1 Caucasian Reference Reference
2 South Asian 1.1 2.9 (0.93 – 9.1) 0.94 2.6 (0.84 – 7.9)
3 East Asian -1.2 0.31 (0.04 –
2.5)
-1.004 0.37 (0.05 – 2.8)
4 African, Caribbean,
Middle-East
-0.21 0.81 (0.42 –
1.5)
-0.21 0.81 (0.43 – 1.5)
5 Other -0.25 0.78 (0.20 –
3.0)
-0.31 0.74 (0.19 – 2.8)
Nulliparity 0.53 1.7 (1.1 – 2.7) 0.37 1.4 (0.92 – 2.2)
Multiple pregnancy 0.85 2.3 (1.4 – 4.1) 0.83 2.3 (1.3 – 3.9)
Previous spontaneous
PTD < 34 weeks
0.43 1.5 (0.78 – 1.1) - -
Gestational age at
assessment (wks)
0.03 1.0 (0.96 – 1.1) - -
Nagelkerke R2 0.39 0.39
AUC (95%CI) 0.90 (95% CI 0.88 – 0.93) 0.89 (95% CI 0.87 – 0.93)
PTD preterm delivery < 7 days
aRegression coefficients of the predictors in the model were shrunken with a
uniform shrinkage factor 0.92. The intercepts were re-estimated after shrinkage
of the regression coefficients of the predictors to ensure
perfect calibration-in-the-large.
bTransformation of continuous variable ‘quantitative fetal fibronectin’ because
of non-linearity
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Background
The UK Biobank dataset (http://www.ukbiobank.ac.uk/about-biobank-
uk/) is a resource established by the Wellcome Trust, available to re-
searchers based anywhere. Over 500,000 UK participants contributed
extensive health-related data, giving a unique opportunity to investi-
gate predictors of disease.
Data were collected from people aged 40-69, initial assessments
were from 2006–2010 and follow-up is ongoing.
Objectives
To use early life factors and clinical data to predict stroke and recur-
rent stroke. To develop a method to identify participants with stroke
and date of stroke. Strokes and dates can be self-reported via
touchscreen, nurse-led interview, or taken from hospital records. Self-
reported stroke without corroboration is not reliable (REF http://jour-
nals.plos.org/plosone/article?id=10.1371/journal.pone.0137538), and
hospital data is challenging to use.
Methods
We compared self-reported strokes, interview-reported strokes, and
hospital stroke data and tried to ascertain consistency and accuracy.
We estimated the proportion of missing data for key variables.
Results
7669 people out of 502,619 reported stroke at initial assessment. This
was not confirmed in interview for 1068 participants, while 793
people did say they had had a stroke in interview but not via
touchscreen. Only 75% of participants had an interview. Reported
dates of stroke have inconsistencies.
The hospital data uses consultant referral as the unit-of-analysis, so a
single stroke may have multiple rows. 6548 participants had from 1
to 24 strokes. Admittance dates, needed to work out if a participant
has had two strokes or two consultant referrals are incompletely col-
lected, with 23% missing. 846 of the hospital strokes occurred prior
to Biobank recruitment but were not self-reported via touchscreen,
of these 656 were also not picked up at interview.
Missing data in non-stroke predictors can be extensive. For example,
33% did not report age left full-time education, and 67% are missing
cognitive data.
Conclusion
UK Biobank is a huge resource, but poses challenges for researchers.
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Background
We conducted a systematic review and meta-analysis of individual
patient data (IPD) on predictors of diabetic foot ulceration. These
predictors can be used to develop a clinical prediction rule for health
professionals working directly with patients.
Objectives
To develop a clinical prediction rule
Methods
Using IPD from nine studies (14897 patients), we chose candidate
predictors based on (i) clinical plausibility, (ii) availability, (ii)
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 5 of 44consistency of definition, and (iv) acceptable heterogeneity. From 22
variables, this left six candidates: age, gender, diabetes duration,
monofilament testing, pulses testing, and history of ulceration to be
used in a two-step meta-analysis (11522 patients). We used a tenth
externally held dataset (1489 patients) – not available to the project
team – for validation. Predictors were considered validated if the ex-
ternal dataset’s results were consistent with meta-analysis results and
they achieved statistical significance.
Results
Three predictors were validated in the external dataset: an inability
to feel a 10g monofilament, any absent pedal pulse and ulcer history,
all binary. Two non-validated predictors were age and diabetes dur-
ation – generally considered highly plausible predictors of diabetes
complications. They are also continuous variables, which have more
statistical power than corresponding categorical variables. We there-
fore compared logistic regression models using the three validated
predictors and all six predictors using discrimination (ROC plots and
area under the curve) and calibration plots. The models using the
three validated predictors were not lower performing than the
models using six predictors.
Discussion
The three validated predictors are all foot-specific. The non-validated
predictors are all “systemic”. It may be that in the prediction of foot
ulcer, data on foot health is more informative than data on the
whole patient.
Conclusion
Understanding the clinical context and sound statistical methods are
important in the selection of predictors.Fig. 1 (abstract P10). Example results from one studyP11
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Background
Taiwan patient safety reporting system 2016 annual report states
that “communication factor” caused by an event 41% belongs to “be-
tween medical staff and patients” communication problems.
Objectives
Make use of the simple, easy-to-understand questions on the Shared
Decision Making platform to provide a clear and complete explan-
ation of the medical staff's interpretation, cross-comparison, assess-
ment, patient selection, and patient support make decisions, express
their willingness to accept and exercise medical consent.
Methods
This study will collect the diagnostic statements of all diseases re-
lated to thyroid cancer with radioactive iodine 131, purpose of the
treatment, the methods of implementation, the possible complica-
tions, the success rate and the risk of non-treatment, the treatment
alternatives and post-treatment precautions, health status, patient
preferences, patient values and so on into the database so that thephysician can discuss directly with the patient from the platform to
display the relative information needed by the patient to check,
which may be appropriate to integrate into the patient Questions
and consideration of the problem, to help patients make the most
appropriate way to check this.
Results
This study is based on the Iodine 131 examination project of Chang
Gung Memorial Hospital, Kaohsiung Medical Center and the two
major concepts of Evidence-Based Medicine and Shared Decision
Making. I-131 Shared Decision Platform architecture is divided into
five parts: Patient Search System, Shared Decision Making System,
Health Education System, Evidence-Based Medicine System, Data Re-
pository System.
Conclusion
To guide patients and their families in structured steps to make im-
portant considerations. After discussions between both doctors and
patients to reduce their mutual cognitive deficits, they also have
three elements of knowledge, communication and respect. They
have reached the philosophy of “Quality, Efficiency and service” so as
to obtain the best and feasible treatment, protect the patients’ med-
ical interests and enhance the quality of medical care.
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BACKGROUND: Risk prediction models which incorporate the FOBT
with other colorectal cancer risk factors have demonstrated increased
sensitivity compared with FOBT alone. EHRs from primary care have
a rich level of data and may add a further dimension to risk predic-
tion models. The aim of the study was to determine the availability
of GP data for key predictors of colorectal cancer in the screening
population and whether we can use this additional information to
make more accurate screening referral decisions.
METHODS: The Health Improvement Network (THIN) database was
used to define a screening population by identifying practices which
receive electronic bowel cancer screening programme notifications.
A prediction model combining the FOBT with other clinical predic-
tors was developed using Cox Regression and multivariable fractional
polynomials with backwards elimination. For internal validation, opti-
mism adjusted performance metrics were determined using boot-
strapping and absolute risk predictions were estimated.
RESULTS: The screening cohort derived from THIN gave 292,168 pa-
tients. The Cox Regression model which included the FOBT result
(n=98,303, 1197 colorectal cancer/polyps) had 13 predictors and 2 in-
teractions including; MCV, various symptoms/diagnoses and whether
previous polyps had been diagnosed. The optimism adjusted per-
formance metrics gave a; C-statistic of 0.850, c-slope of 0.991, D stat-
istic 2.298 and R2 of 0.558. A model investigating negative results
only (n = 95,792, 587 colorectal cancer/polyps) included a similar pat-
tern of variables. Performance metrics included a C-statistic of 0.650,
C-Slope of 0.944, D statistic 0.836 and R2 of 0.144.
CONCLUSIONS: This study has shown that a screening cohort can be
derived from a primary care database using the electronic bowel
cancer screening programme notifications. The prediction models es-
timate an individual’s absolute risk of colorectal cancer. Additional
data could be drawn from primary care onto the Bowel Cancer
Screening system using the NHS Spine to contribute to a referral
algorithm.
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Background: Performance of cardiovascular disease (CVD) risk predic-
tion models for the general female population in women with a his-
tory of hypertensive disorders of pregnancy (HDP) is not established.
Objectives: Assess predictive performance of the Framingham Risk
Score (FRS), Pooled Cohort Equations (PCE) and Systematic Coronary
Risk Evaluation model (SCORE) in women with a history of HDP, com-
pare these to women without, and determine the effects of models’
recalibration or refitting on predictive performance.
Methods: We included 29,751 women of whom 6,302 had a history
of HDP and 17,369 had not. Model performance was assessed with
calibration (calibration curves, Expected:Observed (E:O) ratios) and
discrimination (C-statistics) for the original, recalibrated and refitted
FRS, PCE and SCORE models. All three models predict a form of CVD,
include classical CVD risk factors as predictors, and have a 10-year
prediction horizon.
Results: In women with and without HDP, calibration showed an
overprediction for FRS and PCE, which decreased after recalibration,
whereas the original SCORE model slightly underpredicted, which im-
proved after recalibration. Discrimination was reasonable for all
models, C-statistics ranging from 0.70-0.81 (women with HDP) and
0.72-0.74 (women without HDP). Refitting improved this slightly with
C-statistics from 0.71-0.83 (women with HDP) and 0.73-0.80 (women
without HDP).
Conclusions: SCORE performed best in women. FRS and PCE overpre-
dicted risk in women with and without HDP, but improved after re-
calibrating and refitting the models. No separate model for women
with a history of HDP as compared to without a history of HDP, des-
pite their higher baseline risk, seems necessary.
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Objective
To evaluate four approaches used to provide dynamically updates of
personalized predictions for a binary outcome based on a repeatedly
measured biomarker: likelihood two-stage method (2SMLE), likeli-
hood joint model (JMMLE), Bayesian two-stage method (2SB) and
Bayesian joint model (JMB).
Method
We applied the four approaches to predict the development of ges-
tational trophoblastic neoplasia (GTN) based on age and repeated
measurements of human Chorionic Gonadotropin (hCG), using data
from the Dutch Central Registry for hydatidiform moles at theRadboudumc in Nijmegen. We assessed the predictive power using
the area under the ROC curves, and obtained dynamically updated
predictions for new patients.
Results
The JMMLE failed to achieve convergence due to incomplete
optimization. The remaining three approaches (2SMLE, 2SB and JMB)
gave basically the same estimates, but with slightly higher posterior
parameter estimates of the binary submodel of JMB. Using all avail-
able data, the three models equivalently showed excellent predictive
power. The updated subject-specific predictions for new patients
were approximately the same.
Conclusion
This study provides comprehensive explanation and R syntax for a
toolbox of approaches to obtain updated predictions of a binary out-
come based on newly available measurements.
Keywords
Longitudinal data, binary outcome, dynamic prediction, two-stage
model, joint model, GTN, hCG.
P15
How accurately do trialists pre-specify sample sizes for test
evaluation trials? The experience in NIHR funded trials in the HTA
and EME programmes
J. Deeks1,2,3, L. Archer1, V. Cheed2, K. Handley2, C. A. Hewitt2, N.
Marchevsky2, S. Mehta2, L. Quinn1, A. Sitch1,3, Y. Sun2, Y. Takwoingi1,3, K.
Tryposkiasdis2, R. Woolley2, Q. Zhou2,4, S. Mallett1,3
1Test Evaluation Research Group, Institute of Applied Health Sciences,
University of Birmingham, Edgbaston, Birmingham B15 2TT, United
Kingdom; 2Birmingham Clinical Trials Unit, Institute of Applied Health
Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT,
United Kingdom; 3NIHR Birmingham Inflammatory Biomedical Research
Centre, University of Birmingham, Edgbaston, Birmingham B15 2TT,
United Kingdom; 4First Affiliated Hospital, Sun Yat-Sen University, China
Correspondence: J. Deeks
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P15
Background: Investigators often struggle to identify appropriate
methods for computing sample size for test evaluation studies, and
there is often little data available to inform the assumptions made.
Objective: To review methods used for sample size calculation for tri-
als of tests and assess the validity of the assumptions made in com-
parison with the experience of the trial.
Method: Final reports from the NIHR Health Technology Assessment
(HTA) and Efficacy and Mechanism Evaluation (EME) programmes for
all studies evaluating tests were identified. Sample size calculations
were identified and classified according to (i) the study outcome and
(ii) the method used. Assumed values for key parameters in each
sample size calculation were compared with the estimates observed
in the studies. Details of any sample size revisions undertaken were
identified and reported. All assessments were initially undertaken in-
dependently in duplicate and consensus reached through team
discussion.
Results: 45 reports containing 53 test evaluation studies were identi-
fied; 46 studies of accuracy or agreement and 15 of the impact of
test use. Sample size calculations were given for 37(80%) of the ac-
curacy and agreement studies using precision based (12), power for
differences in paired proportions (10) or independent proportions (9)
or compared with a fixed value (3), or other methods (3). 14 (93%) of
the impact studies reported calculations of power for differences in
independent groups (11), precision (1), or another method (1). 22
(41%) studies reported sample size revisions because of changes in
disease prevalence (7), recruitment (12) or other reasons (3). Ob-
served prevalence varied between 4% and 400% of that assumed in
sample size calculations.
Discussion: Uncertainty in estimates of prevalence is rarely
accounted for in sample size calculations, and often requires
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 7 of 44adjustments to be made during the study. Within study monitoring
of prevalence is required during studies of test accuracy and impact.
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Background: Linked evidence or model based evaluations of tests
are recommended and frequently used to predict health benefit and
assess cost effectiveness. The validity of a linked evidence assess-
ment depends on whether it appropriately models the mechanisms
by which tests impact on patient outcomes.
Objective: To assess the extent to which model based evaluations of
point-of-care tests appropriately account for the effects and impact
of changes in timing of tests on patient health and costs.
Method: We reviewed model based evaluations of point-of-care tests
published between 2004 to 2017 identified by systematic searches of
MEDLINE, EMBASE, CINAHL, NHS EED, PsychInfo and HEED. Each
model was evaluated for the patient outcomes considered, whether
the model estimated the impact of reduced time to diagnosis on
health status and costs, and whether societal costs were included.
Results: 74 model based evaluations met the inclusion criteria, of
which 54 compared point-of-care tests with a slower laboratory
counterpart. Of these, only 39% assessed the economic benefits and
37% the health benefits of faster diagnosis. Only 32% assessed the
impact on patient health; intermediate outcomes such as rates of
correct diagnosis were used instead. 95% of models did incorporate
evidence on test accuracy and consider the impact of false positive
and false negative results.
Discussion: Many model based evaluations fail to capture the effects
of point of care tests related to advancing the time to diagnosis and
treatment, reduced anxiety and potential cost impact for society and
the healthcare system. Neither do they consider the impact of testing
on patient health beyond that related to changed accuracy. Ensuring
models incorporate the changes in testing pathways associated with
early testing, and obtain empirical evidence to populate decision
models will lead to model based evaluations that better reflect the
impact of point-of-care technologies.
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Background:
Candidate predictors are often selected in a non-systematic way, likely
informed by a-priori beliefs as to which are clinically important, al-
though often limited by the availability of existing data and variablesrecorded. More formal ways of identifying candidate predictors include
literature or systematic reviews and expert opinions. However there is
no recommended approach for selecting candidate predictors.
Objective:
To explore the use of a Delphi process in selecting candidate predic-
tors for use in the development of a prognostic model for Atrial Fib-
rillation (AF).
Methods:
A selection of AF expert healthcare professionals were invited to par-
ticipate in a Delphi process to select candidate predictors from a
group of patient characteristics. This process consisted of completing
multiple surveys (rounds) with the aim of gaining consensus
amongst the participants for each patient characteristic. Each charac-
teristic was rated independently (using a Likert scale) on how import-
ant it is in predicting recurrence of AF. When consensus was
reached, the results were analysed and the characteristics were or-
dered from the most to the least predictive.
Results:
Three rounds of the Delphi survey were completed, with the addition
of a consensus meeting which concluded in 217 days. In round 1, 57
of 120 characteristics gained consensus (47.5%). In round 2, 35 of 63
characteristics gained consensus (55.6%) and in round 3, 11 of 28
characteristics gained consensus (39.3%). At the consensus meeting
the remaining 17 characteristics (14.2%) were discussed and subse-
quently gained consensus.
Conclusions:
Undertaking a Delphi process requires a large amount of time in
which to complete and requires commitment from each individual
within the expert group to adequately find the most predictive pa-
tient characteristics for recurrence of AF. Overall the Delphi process
works efficiently when combining a group of expert’s knowledge to
identify candidate predictors to use in developing the prognostic
model.
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Background: Test accuracy reviews are increasingly published in the
literature and their results are used in making clinical and policy de-
cisions. In contrast to clinical trials, there has been little research into
the determinants, magnitude, and impact of optimal sample size
needed for test accuracy studies.
The objective of our study is to assess the proportion of test accuracy
systematic reviews that consider sample size when analyzing and
interpreting results.
Methods: We conducted a methodological systematic survey of test
accuracy systematic reviews published in 2016 and 2017. We are
reviewing a 1:1 stratified random sampling of 280 Cochrane vs. non-
Cochrane systematic reviews. We will calculate the proportion of sys-
tematic reviews discussing sample size in the results, discussion and
conclusion of included reviews. For each systematic review, we will
calculate the preferred sample size required for accurate results using
an equation that integrates the values of prevalence, margin of error
and values of sensitivity or specificity (1). We will report the propor-
tion of reviews that meet the minimum sample size.
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 8 of 44Results: We are in the process of completing this work and we will
have the results ready at the time of the presentation.
Conclusion: The findings of this study will inform the test accur-
acy researchers community and clinicians about the current
practice of considering sample size as a factor that may affect
the quality of the results in both Cochrane and non-Cochrane
reviews. We will also explore the frequency that systematic re-
views achieve a preferred minimum sample size to appropriately
calculate test accuracy. This will work will inform future initia-
tives to empirically assess the effect of imprecision in test ac-
curacy reviews.
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Background: Non-ST Elevation Acute Coronary Syndrome (NSTE-
ACS), comprising unstable angina and Non-ST Elevation Myocar-
dial Infarction is the leading cause of emergency hospitalization
in Europe and a leading cause of death and disability. Different
treatment strategies according to patient risk status are recom-
mended by both National Institute for Health and Care Excel-
lence and the European Society for Cardiology. Although
validated risk scores exist to determine a patient’s risk level, no
randomised controlled trial has tested the effectiveness of ap-
plying an ACS risk stratification tool on the use of guideline
recommended treatments and assessed impact on clinical
outcomes.
Objectives: The UKGRIS (ISRCTN29731761) trial will evaluate the ef-
fectiveness of the systematic application of the GRACE risk score on
the use of guideline recommended care and major adverse cardio-
vascular events (MACE).
Methods: 2-arm cluster randomised trial. At least 30 UK
hospitals randomised 1:1 to GRACE score-based or standard
care to determine NSTE-ACS case management. GRACE risk
scoring in randomised sites is accompanied by specific Class I
guideline recommended processes to follow. (eg pharmacother-
apies, invasive coronary strategy, cardiac rehabilitation).
Standard care cluster patients are managed as per local policy,
but, crucially, GRACE risk scoring is not performed. Endpoints
are (co-primary) guideline uptake and composite MACE and(secondary) unscheduled revascularization, duration of inpatient
stay and quality of life, all at 12 months. Long term outcomes
data will be obtained from routine Electronic Health Records
and clinical registries, including Hospital Episode Statistics, and
National Institute for Cardiovascular Outcomes Research data. A
harmonised international protocol with the AGRIS trial
(ACTRN12614000550606) will allow planned individual patient
data meta-analysis of long term outcomes.
Results: UKGRIS opened March 2017 and is recruiting successfully,
with 1075/3000 patients from 30/30 hospitals.
Conclusion: The UKGRIS trial will test the clinical impact of the use of
a risk prediction model in an urgent care setting.P20
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Background: Pre-test likelihood models recommended in current US
guidelines (and 2010 UK guidelines) have been shown to over-
estimate the probability of coronary artery disease (CAD). The 2010
UK Guidelines mandating invasive coronary angiography (ICA) for
PTL>60% raised concerns of too many non-diagnostic referrals.
Objectives: To use data from the CE-MARC (N=752, single centre, re-
cruited 2006-2009) diagnostic accuracy and CE-MARC2 (N=1202, six
centres, recruited 2012-2015) intervention trials to develop and valid-
ate a multivariable logistic PTL model, and to externally validate the
Duke and CAD Consortium models. Both trials recruited patients with
stable chest pain suitable for revascularization if required, the latter
required Duke Risk PTL of 10-90% and excluded non-cardiac chest
pain.
Methods: From CE-MARC, 675 patients without prior AMI/ACS (650
had known CAD status by ICA) were used, while 264 CE-MARC2 pa-
tients (with known ICA outcome and no prior AMI/ACS) plus 105
anonymised angiography patients selected for Duke PTL <10%,>90%
were used. The new model was developed in CE-MARC, and vali-
dated in CE-MARC2, while the existing models were externally vali-
dated in each dataset. Discrimination (c-statistic) was estimated and
calibration assessed by fitting terms for calibration in the large and
logistic miscalibration to the existing logistic risk models.
Results: In both datasets, all models had similar discrimination (c-
statistic range 0.75 to 0.77). The Duke Clinical Risk score over-
estimated average prevalence of CAD in these datasets, and gener-
ated PTLs too extreme after adjusting for difference in average
prevalence. The CAD Consortium models under-estimated prevalence
of CAD in both datasets, but generated appropriate PTL estimates
once this under-estimation was adjusted for.
Conclusion: Despite similar discrimination, the Duke Clinical Risk
score was poorly calibrated, even after adjusting for PTL over-
estimation. The CAD Consortium models only required preva-
lence adjustment before being well-calibrated. The new CE-
MARC model was well-calibrated, but requires further external
validation.
Table 1 (abstract P20). Summary of model performance
Model Discrimination
(c-statistic)
Calibration in
the large (alpha)
Logistic miscalibration
(beta)
CE-MARC: n=675, Mean age 59.4, 61.8% male, Median CAD PTL by [Duke Clinical/CAD
Consortium Basic/Clinical] = [56.2%, 18.3%, 17.6%]. CAD detected 235/650 (36.2%)
CE-MARC (2016) 0.779 (0.742,
0.814)
NA NA
Duke Clinical Risk
Score (1993)
0.763 (0.725,
0.800)
-1.108 (-1.305,
0.911); P<0.001
-0.298 (-0.416, -0.180);
P<0.001
CAD Consortium
(2012) Basic
0.770 (0.733,
0.806)
0.713 (0.532,
0.893); P<0.001
-0.015 (-0.131, 0.101);
P=0.803
CAD Consortium
(2012) Clinical
0.762 (0.725,
0.7995)
0.822 (0.639,
1.005); P<0.001
-0.051 (-0.159, 0.057);
P=0.354
CE-MARC2+ (n=369, Mean age 59.6, 43.4% male, Median CAD PTL by [Duke
Clinical/CAD Consortium Basic/Clinical] = [67.4%, 16.8%, 14.8%]. CAD detected
158/369 (42.8%)
CE-MARC (2016) 0.777 (0.731,
0.824)
0.045 (-0.190,
0.280); P=0.709
0.028 (-0.214, 0.269);
P=0.823
Duke Clinical Risk
Score (1993)
0.752 (0.704,
0.801)
-1.016 (-1.265,
-0.766); P<0.001
-0.207 (-0.363, -0.050);
P=0.010
CAD Consortium
(2012) Basic Model
0.755 (0.706,
0.803)
0.738 (0.507,
0.969); P<0.001
-0.007 (-0.182, 0.169);
P=0.940
CAD Consortium
(2012) Clinical
0.752 (0.703,
0.800)
0.866 (0.629,
1.103); P<0.001
-0.054 (-0.121, 0.105);
P=0.507
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The objective of this research is to evaluate the predictive perform-
ance of regression methods to develop clinical risk prediction models
using multicenter data, and provide guidelines for practice.
To this end, we compared the predictive performance of standard lo-
gistic regression, generalized estimating equations, random inter-
cepts logistic regression and fixed effects logistic regression. First, we
presented a case study on the diagnosis of ovarian cancer using data
from the International Ovarian Tumor Analysis group (IOTA). Subse-
quently, a simulation study investigated the performance of the
different models as a function of the amount of clustering, develop-
ment sample size, distribution of center-specific intercepts, the pres-
ence of a center-predictor interaction and the presence of a
dependency between center effects and predictors. During valid-
ation, both new patients from centers in the development dataset
and from new centers were included.
The results showed that sufficiently large sample sizes lead to cali-
brated predictions under conditional models and miscalibrated predic-
tions under marginal models. Small sample sizes led to overfitting and
unreliable predictions. This miscalibration was worse with more heavily
clustered data. Calibration of random intercepts logistic regression was
better than that of standard logistic regression even when center-
specific intercepts were not normally distributed, a center-predictor
interaction was present, center effects and predictors were dependent,
or when the model was applied in a new center.In conclusion, to make reliable predictions in a specific center, we
recommend random intercepts logistic regression.
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Introduction: Decisions about test availability for patient care are
often based on limited evidence. Faecal calprotectin (FC) testing has
been approved by NICE for the differential diagnosis of inflammatory
bowel disease and irritable bowel syndrome in UK primary care in
adults with unexplained abdominal complaints. The decision was
based solely on evidence from secondary care. However, transferabil-
ity of test accuracy estimates between settings cannot be assumed
when patient populations differ between settings. We aimed to re-
assess the evidence against a primary care pathway with FC testing
to evaluate what we know about test accuracy of FC testing in pri-
mary care.
Methods: We updated the previous test accuracy review [1] of FC
testing with colonoscopy as the reference standard. Meta-analyses in
R version 3.4.1 explored heterogeneity.
Results: Thirty-eight studies were eligible including five from primary
care. The studies’ patient populations, however, resembled a con-
tinuum from primary to secondary care. None of the studies suffi-
ciently addressed the research question. Primary care studies either
defined the target disease broader than the intended IBD group or
did not use the preferred reference standard. The studies were highly
heterogeneous in terms of tests and clinical question frequently of-
fering more than one 2x2 diagnostic table for different tests and dif-
ferent clinical questions. Meta-analysing outcomes and investigating
setting as a covariate was not feasible as this would have required
expressing a preference for a test and clinical question and disre-
garding others. Separate exploration of test type and clinical ques-
tion by meta-regression showed that neither can be assumed to be
generic.
Discussion: We are lacking evidence to ascertain the assumed test
performance of FC testing in primary care. Alternative approaches to
simply categorising settings into primary and secondary care are
needed to assess studies for their plausibility to reflect the perform-
ance of FC testing in primary care.
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Studies (GRRAS) were established in 2011. Studies of agreement and/
or reliability are in our experience more often than not part of larger
diagnostic accuracy studies, clinical trials, or epidemiological studies
in which agreement and/or reliability are reported as quality control
by using data of the main study. Unfortunately, the planning of such
minor studies regularly fails to precede its conduct and/or re-
searchers are unfamiliar with central concepts of agreement and
reliability.
Objectives: To propose 5 questions to be addressed in the planning
phase from a statistical point of view in order to secure an appropri-
ate analysis plan for an agreement and/or reliability study that actu-
ally illuminates what it is supposed to illuminate.
Methods: We gathered examples from our consultancy experience
and derived an overview sheet characterizing agreement and/or reli-
ability studies. Then, we identified 5 central questions to fine-tune
the statistical analysis and related these to respective items of
GRRAS.
Results: (1) Do you want to investigate interrater/intrarater agree-
ment or reliability? {Item 1}; (2) Who represents the rater population
of interest? {Item 4}; (3) Which factors shall your model be account-
ing for? {Item 6}; (4) Which indices for agreement and/or reliability
are you aiming for? {Item 13}; (5) What is your statistical analysis
plan? {Item 10}.
Conclusion: GRRAS state explicitly that “Researchers should clearly
state a priori their assumptions, why a certain approach was chosen,
and what was intended to be demonstrated.” However, this is in our
experience alarmingly often not the case. GRRAS have proven to be
most helpful, but consulting on agreement and reliability studies re-
semble a continuous awareness campaign. We hope that our 5 sup-
plementary questions to GRRAS help improving the planning of such
studies which, in turn, are then more focused, more appropriate, and
more easily reported by using GRRAS.
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Background: Response evaluation with PET/CT has potential in
personalizing cancer treatment and evaluating treatment re-
sponse. PET/CT is a powerful assessor due to its ability to differ-
entiate between anatomical and physiological response, but
designing clinical studies is challenging; there is no consensus on
which response criteria to follow, which time points to choose
for scans, and how to establish rules for differentiating between
responders and non-responders.
Objectives: To create an overview of study designs used for response
evaluation with PET/CT and basic methodological characteristics.
Methods: PubMed/MEDLINE and Web of Science were systematically
searched for original articles on response evaluation in cancer, pub-
lished in 2015 and employing at least one baseline and one post-
baseline PET/CT scan.
Results: We could identify 124 studies, 61% being prospective
and the remaining 39% retrospective. Fifty-two percent were
prognostic, 28% accuracy studies, and 10% a mix of these. Nor
RCT could be found. Most studies used (one) fixed time points
for imaging and evaluated one predefined rule for responseevaluation. The median sample size was 39. Seventeen medical
areas were represented in the study, the largest group being
lymphomas (N=20, 16%); PET time points varied hugely in this
group.
Conclusion: From a methodological point of view, we expected to
see descriptive, accuracy, and prognostic studies as well as RCTs of
which there were none. Overwhelming 90% of the studies were ei-
ther accuracy and/or prognostic studies. Overall comparative ele-
ments like inclusion of alternative tracers or modalities, several
follow-up time points, variation in parameters (SUVmax, SUVmean,
SUVpaek, SUL, MTV) and summary measures (absolute or relative)
were less frequent than desirable. There is a noticeable gap between
the kinds of studies currently used in response evaluation with PET/
CT on the one hand and those we would expect for establishing effi-
cient response evaluation schemes based on PET/CT on the other
hand.P25
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Background: Research in cancer biomarkers has expanded in recent
years. However, despite the large number of publications, very few
biomarkers have been successfully implemented in the clinic. Bio-
marker discovery studies may suffer from weak study designs, and
incomplete or biased reporting, rendering them vulnerable to exag-
gerated interpretation of biomarker performance. Spin is a way of
reporting, conscious or unconscious, that makes the study findings
appear more favourable than results justify.
Objectives: We aimed to (1) document and classify spin (i.e., misrep-
resentation and overinterpretation of study findings exaggerating
the performance of the biomarker), and (2) facilitators of spin (i.e.,
practices that facilitate overinterpretation of results), in recent clinical
studies evaluating the performance of biomarkers in ovarian cancer.
Methods: We searched PubMed systematically for all evaluations of
biomarkers in ovarian cancer published in 2015. Studies eligible for
inclusion reported the clinical performance of prognostic, predictive,
or diagnostic biomarkers. Reviews, animal studies, and cell line stud-
ies were excluded. All studies were independently screened by two
reviewers.
Results: In total, 1026 citations were retrieved by our search strategy;
326 studies met all eligibility criteria, of which the first 200 studies,
when ranked according to publication date, were included in our
analysis. One-third (60; 30%) of studies were free of spin, one-third
(65; 32.5%) contained one type of spin, and another third (75; 38%)
contained two or more forms of spin in the article. Spin was classi-
fied into two categories: (1) misrepresentation, (2) misinterpretation.
The most frequent forms of spin identified (Table 1) were: (1) other
purposes of biomarker claimed not investigated (65; 32.5%); (2) mis-
match between intended aim and conclusion (57; 28.5%); and (3) in-
correct presentation of results (40; 20%). Frequently observed
facilitators of spin (Table 2) were: (1) not stating sample size calcula-
tions (200; 100%); (2) not mentioning potential harms (200; 100%);
and (3) not pre-specifying a positivity threshold for a continuous bio-
marker (84 of 164 studies; 51.2%);
Conclusion: Reports of studies evaluating the clinical performance of
biomarkers in ovarian cancer frequently have spin. Misinterpretation
and misrepresentation of biomarker performance may account for a
considerable amount of waste in the biomarker discovery process.
Table 1 (abstract P25). Actual forms of spin in clinical studies
evaluating performance of biomarkers in ovarian cancer with examples
Category of spin Type of spin Criteria Spin
frequency,
n = 200
n (%) [95%
CI]
Misrepresentation
a. 1
Incorrect presentation
of results in the
abstract or main text
conclusion
Abstract conclusion OR
main text conclusion for
BM’s clinical
performance is not in
accordance with or is
stronger than results
justify.
Actual spin if all the
following:
a. Exaggerating the
performance of the BM
in the conclusion
despite low
performance measures
reported in the results;
b. Claiming effect of the
BM despite statistically
non-significant results;
c. Claiming effect
despite not providing
imprecision or statistical
test (confidence interval
or P values) between
different biomarker
models tested or patient
groups (subgroups);
40 (20%
[15% -
26%])
Frequency
in abstract
conclusion:
14 (7%
[4% -
12%])
Frequency
in main
text
conclusion:
37 (18.5%
[14% -
25%])
a. 2 Mismatch between
results reported in
abstract and main text
Results reported in the
abstract is not in
accordance with results
reported in main text.
Actual spin if all the
following:
a. Results reported in the
abstract contains
statement in which
statistical significance is
claimed, despite not
providing imprecision or
test of significant (CI or
p-values) in results re-
ported in the main text;
b. Selective reporting of
statistically significant
outcomes in the abstract
compared to the results
reported in the main
text;
c. Results reported in the
abstract that do not
match results provided
in the main text;
33 (16.5%
[12% -
23%])
a. 3 Mismatch between
results reported and
the title
The title contains
wording
misrepresenting BM’s
clinical performance
compared to results in
the main text;
11 (5.5%
[3% -
10%])
Misinterpretation
a. 4
Other purposes of
biomarker claimed not
pre-specified and/or
investigated
Abstract conclusion OR
main text conclusion
contains statement
suggesting BM purposes
Total: 65
(32.5%
[26% -
40%])
Table 1 (abstract P25). Actual forms of spin in clinical studies
evaluating performance of biomarkers in ovarian cancer with examples
(Continued)
Category of spin Type of spin Criteria Spin
frequency,
n = 200
n (%) [95%
CI]
not pre-specified and/or
investigated.
Frequency
in abstract
conclusion:
36 (20.5%
[13% -
24%])
Frequency
in main
text
conclusion:
60 (30%
[24% -
37%])
a. 5 Mismatch between
intended aim and
abstract or main text
conclusion
Abstract conclusion OR
main text conclusion for
BM’s clinical
performance is stronger
than study design.
Actual spin if all the
following:
a. The main text
conclusion contains
statement in which BM
utility is claimed despite
not evaluating clinical
effectiveness (i.e. useful);
b. The main text
conclusion contains
statement in which BM
performance
improvement is claimed
despite not evaluating
incremental measures
(i.e. improve);
c. The main text
conclusion contains
statement that uses
causal language for
BM(s) being assessed
despite the use of a
nonrandomized design;
Total: 57
(28.5%
[23% -
35%])
Frequency
in abstract
conclusion:
41 (20.5%
[15% -
27%])
Frequency
in main
text
conclusion:
31 (15.5%
[11% -
21%])
a. 6 Other benefits of BM
claimed not pre-
specified and/or
investigated
The main text
conclusion contains
statement claiming BM
benefits not pre-
specified and/or
investigated.
10 (5%
[3% - 9%])
a. 7 Extrapolation from
study participants to a
larger or a different
population
The main text
conclusion contains
statement that
extrapolates BM’s clinical
performance to a larger
or a different population,
not supported by
recruited subjects.
10 (5%
[3% - 9%])
* All results presented in abstract and main text, excluding supplementary
material.
**Abbreviations: BM, biomarker; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
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Fig. 1 (abstract P27). External validation calibration plots for the
Table 2 (abstract P25). Facilitators of spin in clinical studies evaluating
performance of biomarkers in ovarian cancer
Potential facilitators of spin Spin frequency, n= 200
n (%) [95% CI]
Not stating sample size calculations 200 (100% [98% -
100%])
Not mentioning potential harms 200 (100% [98% -
100%])
Not pre-specifying a positivity threshold for continuous
biomarker
84/164* (51.2% [43% -
59%])
Incomplete or not reporting imprecision or statistical test
for data shown
26 (13% [9% - 19%])
Study objective not reported or unclear 24 (12% [8% - 18%])
* 164 articles included evaluation of continuous biomarkers
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Background
Adoption of a clinical test into NHS practice requires evidence on its
accuracy, usability, clinical utility, affordability and cost-effectiveness.
This entails evaluating the changes in clinical and economic out-
comes to the care pathway (ie journey that patients make through
the healthcare system) resulting from potential adoption. Methods
for evaluating utility and cost-effectiveness are well established, and
new methods are being developed. However, little research has been
done to evaluate the processes that provide the data for these evalu-
ations, ie care pathway analysis, modelling, implementation and
evaluation.
Objectives
We aim to identify new methodologies for care pathway analysis. In
this instance we evaluated, through a case study, the utility of col-
lecting and analysing NHS local guidelines.
Methods
The pathways used to recognise patients with suspected sepsis were
compared between 14 Trusts and with the NICE guidelines. Recom-
mended symptoms and thresholds were identified and categorized.
Results
The recommended physiological signs to consider for early identifica-
tion of patients with suspected sepsis were consistent across sites
and with NICE guidelines, but thresholds were different. The number
of steps that would lead to identifying patients for review and initi-
ation of the Sepsis 6 bundle was also different across Trusts. This
leads to a different number of patients treated for sepsis across UK
independently of the true disease prevalence.
Conclusion
The analysis of local guidelines:
1. clarified the physiological signs that influence the clinical
decision making during the pathway;
2. supported the development of a high-level map common to
the majority of Trusts, first step for care pathway modelling;
3. provided insights about variability in patient care across
different UK.
In conjunction with data from the Hospital Episode Statistics, the al-
gorithms described in the guidelines can be powerful tools to calcu-
late the ranges for prevalence and distributions of outcomes
associated to specific diseases.P27
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Background
Correctly determining diabetes subtype is important to ensure opti-
mal treatment and education, but is often difficult, particularly in
young adults, where misclassification is common. We aimed to de-
velop and externally validate two clinical prediction models combin-
ing clinical features and GAD autoantibodies (marker of Type 1
immune process) to identify patients with type 1 diabetes (T1D), re-
quiring early insulin therapy.
Methods
We used 1,352 participants diagnosed with diabetes aged 18-50
years from Exeter cross-sectional cohorts to develop two logistic re-
gression models predicting requirement for early insulin therapy:1)
using clinical features (age at diagnosis and BMI); 2) clinical features
and GAD (n=1036 with GAD available). Discrimination and calibration
performance of the models were estimated using internal bootstrap
validation. External validation of the models was performed in 701
and 657 participants taken from the Young Diabetes in Oxford study.
Results
Prevalence of T1D was 13.24% & 13.51% in the development samples
versus 19.12% & 18.57% in the external validation data.
The model with clinical features alone was highly discriminative at de-
velopment (c-statistic 0.90 [0.88, 0.93]); internal bootstrap validation
showed a small optimism (0.0006). Adding GAD improved develop-
ment model (c-statistic 0.96 [0.95-0.97]); internal bootstrap validation
showed a small optimism (0.0009). In the external validation, both
models still showed excellent discrimination (clinical features c-statistic
0.86 [0.82, 0.89]; clinical features + GAD c-statistic 0.92 [0.89, 0.95]).
Hosmer-Lemeshow test for calibration was non-significant at develop-
ment in both models (p=0.95 & 0.39). However, there was evidence of
overall miscalibration at external validation (p = 0.004 & 0.007), with
both models over-estimating in the higher risk groups (Fig 1).
Conclusion
We developed highly discriminatory models for classifying patients re-
quiring early insulin therapy. Addition of GAD improved the model per-
formance. Further investigation is required to identify the reason for
the miscalibrations at the highest probabilities in external validation.clinical features model (left) and clinical features + GAD
model (right)
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Background: Clinical prediction models (CPMs) are widely used in
healthcare to support medical decision-making based on patient-
specific characteristics. Over the past decade, there has been an ex-
ponential growth of peer-reviewed articles regarding the develop-
ment of CPMs. However, the majority of these models lack proper
validation and transparent description. As a result, CPMs often do
not reach their full potential.
Objectives: We aimed to develop an open online platform enabling
users to create, validate, integrate, and apply CPMs in daily medical
practice.
Methods: An innovative platform was developed to enable regis-
tered users to add CPMs and describe them with maximum transpar-
ency in concordance with published guidelines (TRIPOD statement).
On the Evidencio platform, researchers and healthcare professionals
can create CPMs based on pre-specified regression formulas, custom
formulas, or run R code formulas. Tools were developed to facilitate
validation of online CPMs (model discrimination and calibration)
based on institutional patient data. Model developers maintain own-
ership of their data and intellectual property of created CPMs.
Methods to integrate CPMs using an application programming inter-
face (API) were explored.
Results: The platform is available online and currently contains over
800 CPMs covering 30 healthcare specialties. Over 350 CPMs are
available as open source. A little over 230 external validations were
performed so far. Models on the Evidencio platform are easily inter-
operable, allowing for the calculation of multiple outcomes at once
(composite models) or in a sequential format (dynamic protocols). It
was found feasible to integrate CPMs on Evidencio in third party ap-
plications through an API, enabling their use in digital protocols, ex-
ternal websites, and the electronic health records.
Conclusion: An online platform for CPMs was developed and is avail-
able on www.evidencio.com. Future updates should include add-
itional features on model recalibration following validation, semi-
automatic variable mapping, and development of a patient-centered
graphical representation of model outcomes.
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Background: Multiple statistical models predicting lymph node in-
volvement (LNI) in prostate cancer (PCa) patients exist to support
clinical decision-making regarding pelvic lymph node dissection
(PLND).
Objectives: We aimed to validate existing models predicting LNI in a
Dutch PCa patient cohort.Methods: Sixteen prediction models were validated using a Dutch
patient cohort of 1,001 men who underwent extended PLND be-
tween October 2008 and May 2017. Patient characteristics included
serum prostate specific antigen (PSA), clinical tumor (cT) stage, pri-
mary and secondary Gleason scores, number of biopsy cores taken,
and number of positive biopsy cores. Model performance was
assessed using the area under the curve (AUC) of the receiving oper-
ator characteristic (ROC) curve. Calibration plots were used to
visualize over- or underestimation of the models.
Results: Lymph node involvement was identified in 276 (28%) pa-
tients. Patients with LNI had a higher PSA, higher primary Gleason
pattern, higher Gleason score, higher number of harvested nodes,
higher number of positive biopsy cores, and higher cT stage, com-
pared to patients without LNI. Predictions generated by the 2012 Bri-
ganti nomogram (AUC = 0.76) and the MSKCC web-calculator
including biopsy core information (AUC = 0.75) were found most ac-
curate. Underestimation of LNI probability was present when looking
at patients with a predicted probability below 20%.
Conclusion: Models predicting LNI in PCa patients were externally
validated in a Dutch patient cohort. The 2012 Briganti and the
MSKCC nomograms were the most accurate prediction models
available.
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Background: Clinical prediction models support decision making on
the performance of pelvic lymph node dissection (PLND) in prostate
cancer (PCa) patients. However, international guidelines recommend
different risk thresholds to select patients who may benefit from
PLND.
Objectives: We aimed to quantify the cost-effectiveness of using dif-
ferent risk thresholds for predicted lymph node involvement (LNI) in
PCa patients with the Briganti nomogram (2012) to inform decision
making on omitting pelvic lymph node dissection (PLND).
Methods: Four different thresholds (2%, 5%, 10% and 20%) used in
practice for performing PLND were compared using a decision ana-
lytic model, using the 20% threshold as reference. Baseline character-
istics for the hypothetical cohort were based on an actual Dutch
patient cohort containing 925 patients who underwent extended
PLND with risks of LNI predicted by the 2012 Briganti Nomogram.
Compared outcomes consisted of quality adjusted life years (QALYs)
and costs. The best strategy was selected based on the incremental
cost effectiveness ratio (ICER) when applying a willingness to pay
(WTP) threshold of €20,000 per QALY gained. Probabilistic sensitivity
analysis was performed with Monte Carlo simulation to assess the ro-
bustness of the results.
Results: Costs and health outcomes were lowest (€7,207 and 6.22
QALYs) for the 20% threshold, and highest (€9,670 and 6.27 QALYs)
for the 2% threshold, respectively. The ICER for the 2%, 5%, and 10%
threshold compared with the first threshold above (i.e. 5%, 10%, and
20%) were €84,974/QALY, €65,306/QALY, and €28,860/QALY, respect-
ively. Applying a WTP threshold of €20.000,- the probabilities for the
2%, 5%, 10%, and 20% strategies being cost-effective were 0%, 3%,
28%, and 69%, respectively.
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 14 of 44Conclusion: Applying a 20% risk threshold for probable LNI to the
Briganti 2012 nomogram, to inform decision making on performing
PLND in PCa patients is optimal from a health economic perspective.
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Background: Policy making on diagnostics presents huge challenges
which organisations like NICE have tried to address. High amongst
these are that diagnostics have multiple ways in which they can
bring benefit to patients, carers, health services and society. This
makes the task of evaluating the impact and collecting evidence on
those impacts complex. One suggestion how this complexity can be
handled is a clear statement of value proposition, in which devel-
opers are specific not just about how and where the new test will be
used, but also what they expect will be achieved. In this way atten-
tion is directed to aspects of impact which should receive priority in
the evidence development process. We intend to describe the de-
gree to which the concept of value proposition has been used in
NICE’s Diagnostic Guidance. This extends previous work on the use
of end-to-end studies.
Objectives: To explore whether value proposition has been clearly
described in NICE Diagnostic Guidance and whether evidence has
been found which directly demonstrates the aspects of value propos-
ition identified.
Methods: We will extend the approach used in past analysis of the
methodological features of NICE guidance. All NICE diagnostics guid-
ance will be interrogated. We will abstract data on the policy ques-
tion addressed and the underlying value proposition and whether
evidence has been identified on these aspects of value proposition.
Analysis will be qualitative.
Results: This work is in progress.
Conclusion: Value proposition is a potentially useful way for policy
makers to help make sense of the many different ways in which a
test might represent an effective and cost-effective addition to
health care. This project will inform the degree to which the concept
is already being used by one prominent policy-maker, but also offer
ways in which greater use can be made of it in the future. [299]
P32
Prediction of Postpartum Depression Using Machine Learning
methods
S. Ioannou1, G. A. Holtman2, L. L. Peters2,3, H. Burger2, C. H. zu
Eulenburg1
1Department of Epidemiology, University Medical Center Groningen,
University of Groningen, The Netherlands; 2Department of General
Practice & Elderly Care Medicine, University Medical Center Groningen,
University of Groningen, The Netherlands; 3Department of Midwifery
Science AVAG, VU University Medical Center Amsterdam, Amsterdam
Public Health Research Institute, The Netherlands
Correspondence: S. Ioannou
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P32
Background
There is limited data in the application and use of machine learning
techniques to predict postpartum depression. Furthermore, there is
scarce information on how machine learning techniques can be inte-
grated in the epidemiological framework of identifying persons at
risks in clinical psychology.
Objectives
We explore machine learning methods to develop predictive models
for postpartum depression and compare them with current methods
of predictive modeling.Methods
Data is obtained from the Pregnancy Anxiety and Depression (PAD)
prospective cohort study designed to investigate risk factors for ante-
natal and postnatal anxiety and depression. We use data retrieved
from 6,930 participating women by questionnaires providing infor-
mation on social support, anxiety and personality traits, as well as in-
formation on socio-economic status, lifestyle, and stressful life events
during pregnancy. Assessments took place at baseline, 24 and 36
weeks of gestation and 6 months postnatal. We attempt to create
classification and regression models using machine learning tech-
niques such as logistic regression, decision trees, and linear discrim-
inant analysis to predict postpartum depression as assessed by the
Edinburg Postnatal Depression scale ≥ 10. We then apply cross-
validation and bootstrap techniques to compare the predictive valid-
ity, assumptions and interpretability of the methods.
Conclusions
This exploratory study aims to investigate the potential of machine
learning methods for the prediction of postpartum depression risk in
comparison to established statistical techniques with respect to suit-
ability, applicability and accuracy of the methods. As a further step
we aim to compare the predictive assessment, inferential strengths
and weaknesses and statistical pitfalls that may appear from the use
of such methods.P33
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Background
Biomarkers are increasingly used to personalise treatment, and
biomarker-guided trials are the gold standard for testing their clinical
utility. A lack of trials is one of the main obstacles delaying transla-
tion of biomarker discoveries into clinic. Before a trial takes place,
there must be robust evidence for the biomarker’s validity. However,
the extent of evidence required, and how it should be compiled, is
unclear.
Objectives
We have undertaken a literature review to identify biomarker-guided
randomised controlled trials (RCTs) and explore what evidence has
been used to justify inclusion of a biomarker, and how the evidence
was compiled.
Methods
We conducted a systematic search of four databases. Our search
yielded 11399 papers when duplicates were removed. After screen-
ing titles and abstracts, 284 papers remained for full text screening.
After full-text screening, and restricting to papers published in the
past five years, 119 papers were included.
Results
The majority of trials were in the field of oncology (55.5%) with car-
diovascular disease being the second most common (17.6%).
Many trials justified use of a biomarker based on previous retrospect-
ive or pilot studies. Others were based on evidence from literature
reviews, case studies, or in vitro/in vivo work. Some trials provided
strong evidence for biomarker use, citing meta-analyses and previous
RCTs.
Conclusion
To our knowledge, no prior review has systematically identified the
methods used for compiling evidence for inclusion of biomarkers in
previous biomarker-guided RCTs. We have identified large variations
in methods, with several RCTs based on little evidence. We have also
quantified how many of each biomarker-guided design have been
utilised, as well as the clinical areas in which they have been used.
No standard approach exists for gathering evidence to justifying in-
clusion of a biomarker in RCTs, and our further work will focus on op-
timal approaches for doing so.
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Background
The phrase “care pathway” refers to the journey a patient takes dur-
ing an episode of healthcare. Mapping the care pathway for a med-
ical condition is a vital step in the evaluation of a new diagnostic
test, helping developers identify the optimal role of their test; where
it leads to greatest patient and economic benefit. Care pathways can
be established through interviews with relevant medical experts,
which are transcribed and analyzed thematically in software pack-
ages such as NVivo or ATLAS. These packages provide a validated en-
vironment for qualitative research, but are expensive and rigid in
terms of data manipulation and analysis options, thus, have limited
utility.
In a recent project we utilized the R programming language and an
R package called ‘RQDA ‘to thematically analyze interviews designed
to elicit expert opinion on C.diff testing in the UK NHS. The advan-
tage of using R is that it is free, powerful and flexible, plus there is a
strong community of users continually developing and advancing
packages for use in the R environment.
Objective
To outline a potentially novel approach to thematic analysis in R
using the RQDA package. Demonstrated with interview data from an
exploratory study aimed to understand the potential role of a new
point of care test for C.diff, within the UK NHS.
Methods
We interviewed 10 clinicians with expertise in the diagnosis and
management of C.diff infection in the UK NHS. These interviews were
transcribed verbatim and thematically analyzed in R, using the RQDA
package.
Results & Conclusions
This study resulted in the explication of a potentially novel approach
to thematic analysis of interviews to inform care pathway analysis for
new diagnostic tests. It is our view that this new approach is system-
atic, scientifically reproducible and widely available, thus, a useful ap-
proach to communicate to the wider diagnostic community.
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Background
Multinomial Logistic Regression (MLR) has been advocated for devel-
oping clinical prediction models that distinguish between three or
more unordered outcomes. Which factors drive the predictive per-
formance of MLR is still unclear.
Objectives
We aim to identify the key factors that influence predictive perform-
ance of MLR models. Further, we aim to give guidance on the neces-
sary sample size for multinomial prediction model development and
on the usage of penalization during model development.Methods
We present a full-factorial simulation study to examine the predictive
performance of MLR models in relation to the relative size of out-
come categories, number of predictors and the number of events
per variable. Further, we present a case study in which we illustrate
the development and validation of penalized and unpenalized multi-
nomial prediction models for predicting malignancy of ovarian
cancer
Results
It is shown that MLR estimated by maximum likelihood yields over-
fitted prediction models in small to medium sized data. In most
cases, the calibration and overall predictive performance of the
multinomial
prediction model is improved by using penalized MLR. Events per
variable, the number of predictors and the frequencies of the out-
come categories affect predictive performance.
Conclusion
As expected, our study demonstrates the need for optimism correc-
tion of the predictive performance measures when developing the
multinomial logistic prediction model. We recommend the use of pe-
nalized MLR when prediction models are developed in small data
sets, or in medium sized data
sets with a small total sample size (i.e. when the sizes of the outcome
categories are balanced). Our simulation study also highlights the im-
portance of events per variable in the multinomial context as well as
the total sample size.
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Background
Biomarker-guided treatment is a rapidly developing area of medicine.
A biomarker-guided trial is the gold standard approach to testing
clinical utility of such an approach, and several biomarker-guided trial
designs have been proposed. Due to the complexity of some of the
designs they are often difficult to understand in terms of how they
should be implemented and analysed. Further, due to the large num-
ber of different designs available, it is challenging to decide which is
the most appropriate in a particular situation.
Objectives
To develop a user-friendly online tool, informed by a comprehensive
literature review, to guide and inform those embarking on
biomarker-guided trials in terms of optimal choice, design, practical
application and analysis.
Methods
We undertook a comprehensive literature review. All unique
biomarker-guided trial designs were identified and their design fea-
tures, analysis approach and positive and negative qualities de-
scribed. Importantly, a graphical representation of each trial design
was developed, standardised to allow easy comparison of features
across designs. Based on our review we developed our online tool,
‘BiGTeD’ to allow easy and free access to the information gathered.
Results
Our literature review identified 211 papers describing biomarker-
guided trials. Information gathered during the review has been incor-
porated into our newly developed online tool, BiGTeD, a key feature
of which is a clear and interactive graphical representation of each
trial design to aid interpretation and understanding.
Conclusions
Navigating the literature to gain understanding of which biomarker-
guided trial design to choose, and the practical implications of doing
so is difficult. Our online tool, BiGTeD (www.bigted.org) is aimed at
improving understanding of the various biomarker-guided trial
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 16 of 44designs and provides valuable and much-needed guidance on their
implementation in a user-friendly way. Knowledge on how to design,
implement and analyse these trials is essential for testing the effect-
iveness of a biomarker-guided approach to treatment.
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Background
The standard approach of ROC (receiver operating characteristic)
curve analysis considers event (disease) status and marker value for
an individual as fixed over time, however in practice, both the dis-
ease status and marker value can change over time. Individuals who
are disease-free earlier may develop the disease later due to longer
study follow-up. Our comprehensive review on time-dependent ROC
curve analysis (Kamarudin et al., 2017) found that all current estima-
tion methods directly use the observed marker measurements by ig-
noring the presence of possible measurement error.
Objectives
We are proposing a novel method for evaluating the diagnostic efficacy
of a marker at the baseline level accounting for measurement error.
Methods
We propose a joint modelling approach to link the individual-level
deviation of the baseline marker profile from the population mean
and the risk of clinical endpoint. At any time t, we define cases as
diseased individuals prior to t and controls as individuals survive be-
yond t. The estimated random effects at baseline are used to define
the measurement error adjusted marker. We evaluate the proposed
approach in several simulation studies by varying the variance of
measurement error and the strength of association between marker
and risk of disease, and illustrate in real data.
Results
The proposed measurement error adjusted maker performs better
over the observed marker as compared to the true area under the
ROC curve (AUC) with low biases and high coverage percentages.
Conclusion
An observed marker could underestimate the true diagnostic effect-
iveness due to measuerement error and hence useful markers might
be overlooked. The proposed methodology effectively adjust for
measurement error when evaluating the diagnostic effectiveness of a
marker.
Reference
Kamarudin, AN et al. (2017). “Time-dependent ROC curve analysis in medical
research: current methods and applications”. BMC Med Res Methodol 17(1): 53.
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The increasing availability of diagnostic tests and biomarkers is
accompanied by an increase in health economic evaluations of
these tests. However, such evaluations are typically complex and
model-based because tests primarily affect health outcomes indir-
ectly and real-world data on health outcomes are often lacking.
General frameworks for conducting and reporting health eco-
nomic evaluations are available but not specific enough to cover
the intricacies of diagnostic test evaluation. In addition, certain
aspects relevant to the evaluation may be unknown, and there-
fore unintentionally omitted from the evaluation. This leads to a
loss of transparency, replicability, and (consequently) a loss of
quality of such evaluations.
Objectives
To address the abovementioned challenges, this study aims to de-
velop a comprehensive reporting checklist.
Methods
This study consisted of three main steps: 1) the development of an
initial checklist based on a scoping review; 2) review and critical ap-
praisal of the initial checklist by four independent experts; 3) devel-
opment of a final checklist. Each item from the checklist is illustrated
using an example from previous research.
Results
The scoping review followed by critical review by the four ex-
perts resulted in a checklist containing 43 items which ideally
should be considered for inclusion in a model-based health eco-
nomic evaluation. The extent to which these items were included,
or discussed, in the studies identified in the scoping review var-
ied substantially, with 13 items not being mentioned in ≥47
(75%) of the included studies.
Conclusion
As the importance of health economic evaluations of diagnostic tests
and biomarkers is increasingly recognized, methods to increase their
quality are necessary. The checklist developed in this study may con-
tribute to improved transparency and completeness of such model-
based health economic evaluations. Use of this checklist is encour-
aged to enhance their interpretation, comparability, and – indirectly
– the validity of the results.
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Background
Obstructive sleep apnea syndrome (OSAS) is increasingly recognized
as a serious health condition. Currently, OSAS is diagnosed with poly-
somnography (PSG) in sleep clinics or hospitals. However, increasing
waiting lists for sleep tests, and many unnecessary referrals from
general practice for PSG highlight the need for alternative diagnostic
strategies for OSAS.
Objectives
To investigate the impact of using DiagnOSAS, a screening tool to
predict the risk of OSAS in individuals suspected of this condition to
guide PSG referral decisions. on health outcomes and costs, and to
assess its cost-effectiveness in the Netherlands compared to usual
care (no screening tool).
Table 1 (abstract P40). Diagnostic accuracy of the PHQ-9 by reference
standard
Semi-structured
Reference Standard
N studies = 29
N participants = 6,725
N major depression =
924
Fully structured
Reference Standard
N studies = 14
N participants = 7,680
N major depression =
839
Difference across
reference standards
(Semi- Fully)
Cutoff Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
5 0.98 0.55 0.93 0.54 0.05 0.01
6 0.98 0.63 0.91 0.61 0.07 0.02
7 0.98 0.69 0.86 0.69 0.12 0.00
8 0.95 0.75 0.82 0.75 0.13 0.00
9 0.91 0.80 0.74 0.79 0.17 0.01
10 0.88 0.85 0.70 0.84 0.18 0.01
11 0.84 0.89 0.62 0.87 0.22 0.02
12 0.79 0.91 0.57 0.89 0.22 0.02
13 0.70 0.93 0.49 0.92 0.21 0.01
14 0.64 0.95 0.44 0.94 0.20 0.01
15 0.56 0.96 0.35 0.96 0.21 0.00
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A Markov cohort model was constructed to assess cost-effectiveness
of the prediction tool in men aged 50 years. The diagnostic process
of OSAS was simulated with and without the use of the DiagnOSAS
tool, taking into account the risks and consequences of the most se-
vere OSAS effects: car accidents, myocardial infarction and stroke.
Base case cost-effectiveness was based on equal time to OSAS diag-
nosis with and without the use of the prediction tool. In a scenario
analysis cost-effectiveness was assessed assuming that the prediction
tool would halve this time to diagnosis.
Results
Base case results show that, within a 10 year time period, DiagnOSAS
saves €226/patient at a negligible decrease in health outcomes
(<0.01 quality-adjusted life years; (QALYs)), resulting in an incremen-
tal cost-effectiveness ratio of €56,997/QALY. In the scenario with
time-to-diagnosis halved, DiagnOSAS dominates usual care (i.e. is
both cheaper and more effective). For a willingness-to-pay threshold
of €20,000/QALY the probability that using DiagnOSAS is cost-
effective equals 91.7% (base case) and 99.3% (time-to-diagnosis
halved), respectively.
Conclusion
DiagnOSAS appears to be a cost saving alternative for the usual
OSAS diagnostic strategy in the Netherlands. When this prediction
tool succeeds in decreasing time-to-diagnosis, it could substantially
improve health outcomes as well.
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Background: Existing meta-analyses of depression screening tool ac-
curacy have treated clinician-administered semi-structured diagnostic
interviews and lay-administered fully structured diagnostic interviews
as equivalent reference standards for assessing major depressive dis-
order (MDD). Semi-structured interviews are akin to a guided diag-
nostic conversation. Standardized questions are asked, but
interviewers may insert additional queries and use clinical judgment
to decide whether symptoms are present. In contrast, fully structured
interviews are fully scripted. Standardized questions are read verba-
tim, without additional probes. Fully structured interviews are consid-
ered potentially more reliable but possibly less valid for MDD
classification.
Objectives: To compare estimates of diagnostic test accuracy of the
Patient Health Questionnaire-9 (PHQ-9) depression screening tool
when semi- versus fully structured interviews are used as the refer-
ence standard.
Methods: Due to selective cutoff reporting within primary studies
(Levis et al, AJE, 2017), we used an individual participant data meta-
analysis approach to compare accuracy of the PHQ-9 across refer-
ence standards, using accuracy results for all cutoffs for all studies ra-
ther than only published results. Electronic databases were searched
for datasets that compared PHQ-9 scores to MDD diagnosis based on
validated interviews. For PHQ-9 cutoffs 5-15, we estimated pooled
sensitivity and specificity among studies using semi- and fully struc-
tured interviews as the reference standard separately.
Results: Data were obtained from 43 of 53 eligible studies, for a total
of 14,405 participants (1,763 MDD cases). Specificity estimates were
similar across reference standards (within 2%); however, sensitivity
estimates were 5-22% higher (median=18%, at standard cutoff of 10)
when semi-structured interviews were used as the reference stand-
ard compared to fully structured interviews (Table 1).Conclusion: The PHQ-9 more accurately classifies patients when com-
pared to semi- versus fully structured interviews as the reference
standard. Meta-analyses of depression screening tool accuracy
should take into consideration potential differences in reference
standards.P41
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Background: Existing meta-analyses of depression screening tool ac-
curacy have treated clinician-administered semi-structured diagnostic
interviews and lay-administered fully structured diagnostic interviews
as equivalent reference standards for assessing major depressive dis-
order (MDD). Semi-structured interviews are akin to a guided diag-
nostic conversation. Standardized questions are asked, but
interviewers may insert additional queries and use clinical judgment
to decide whether symptoms are present. In contrast, fully structured
interviews are fully scripted. Standardized questions are read verba-
tim, without additional probes. Fully structured interviews are consid-
ered potentially more reliable but possibly less valid for MDD
classification. No studies have assessed whether semi- and fully struc-
tured interviews differ in the likelihood that MDD will be diagnosed.
Objectives: To evaluate the association between interview method
and odds of MDD diagnosis, controlling for depressive symptom
scores and participant characteristics.
Methods: We analysed data collected for an individual participant
data meta-analysis of Patient Health Questionnaire-9 (PHQ-9) diag-
nostic accuracy. Binomial Generalized Linear Mixed Models with a
logit link were fit. An interaction between interview method and
PHQ-9 scores was assessed.
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analyzed. Among fully structured interviews, the odds of MDD diag-
nosis were significantly higher for the Mini International Neuro-
psychiatric Interview (MINI) compared to the Composite International
Diagnostic Interview [OR (95% CI) = 2.10 (1.15-3.87)]. Compared
to semi-structured interviews, fully structured interviews (MINI ex-
cluded) were more likely to diagnose MDD among participants
with low-level depressive symptoms (PHQ-9≤6) [OR (95% CI) =
3.13 (0.98-10.00)], similarly likely among those with moderate-
level symptoms (PHQ-9 7-15) [OR (95% CI) = 0.96 (0.56-1.66)],
and less likely among those with high-level symptoms (PHQ-
9≥16) [OR (95% CI) = 0.50 (0.26-0.97)].
Conclusion: The likelihood of MDD diagnosis appears to depend on
the diagnostic interview used. Meta-analyses on depression screen-
ing tool accuracy should consider methods to account for possible
differential verification bias.Fig. 1 (abstract P41). Probability of MDD diagnosis across depressive
symptom levels for different diagnostic interview methodsP42
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Background
HIV remains a global epidemic especially in low-to-middle income
countries. The acute phase of infection is highly infectious when a
patient is newly infected but the body is yet to generate sufficient
amount of antibodies. Current 3rd generation tests for HIV screening
however miss over half of acute infections.
Objectives
We used stakeholder analysis to explore user scenario and carried
out a cost-effectiveness analysis to explore impact of a new 4th gen-
eration point of care HIV test based on detection of p24 antigen. The
test is likely to be highly sensitive, and offer better linkage to care
and fast time to results (under 15 min).
Methods
We interviewed 5 experts including 4 technology specialists and one
clinician. We reviewed literature to extract evidence on early detec-
tion and treatment, quality of life and costs. We built a test-to-
treatment pathway model to capture key advantages of the new test.
This pathway model is then superimposed on a markov model for
disease progression. We simulated a screening population of 100,000
patients over 30 years on a monthly cycle.Results
Assuming a clinician-led user model in high prevalence countries, com-
paring to the 3rd-gen test, the new test averted 15 transmissions per
100,000 screening population. Its cost-effectiveness, as measured by
the incremental cost-effectiveness ratio (ICER), is US$39,785 per QALY,
or US$35,684 per QALY, when transmission was taken into account.
The main driver of the cost-effectiveness lies with the characteristics of
the screening populations. ICER reached $100,534 per QALY gained
when the test population has an HIV/AIDS prevalence at 1%.
Conclusion
By decomposing test-to-treatment pathway, we are able to quantify
the impact of test characteristics, such as better linkage to care. This
new, more sensitive screening test, has the potential to achieve cost-
effectiveness through target screening in a high prevalence setting.
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Introduction: Evaluations of the impact of malaria rapid diagnostic
tests (RDTs) have shown beneficial effects of RDTs on intermediate
process outcomes, such as reduced time to diagnosis and treatment,
but limited impact on later stage patient outcomes, such as morbid-
ity and mortality. These unclear benefits could be partly due to short-
comings in study design and factors influencing intervention fidelity
(extent to which the test-treatment intervention is delivered as de-
signed). We aim to critically review the designs, outcome measures
and intervention fidelity of studies evaluating the impact of malaria
RDTs on patient-important outcomes and explore factors that may
influence intervention fidelity.
Methods: We are conducting a systematic review of quantitative and
qualitative studies. We have searched relevant electronic databases and
grey literature and included studies based on predefined inclusion cri-
teria. To evaluate the methodological quality of included studies, we are
using the revised Cochrane risk of bias tool for randomized studies (ROB
2.0), the revised Cochrane risk of bias tool for non-randomised studies of
interventions (ROBINS-I), the checklist to assess implementation (Ch-IMP)
for assessing the quality of intervention delivery and an adaptation of the
Critical Appraisal Skills Programme (CASP) tool for qualitative studies.
Two authors have reviewed the search output and are currently extract-
ing data and assessing methodological quality independently, resolving
any disagreements by consensus. We will synthesize information from
quantitative studies narratively and through descriptive statistics and use
a thematic framework analysis approach for qualitative studies.
Results and Discussion: Our electronic searches yielded 2731 hits of
which 123 studies (quantitative (n=72) and qualitative (n=51)) have been
included for data extraction. We will present the review results, including
a graphical classification of key methodological issues affecting malaria
RDT impact studies (see logic framework in Fig. 1) with discussion of con-
siderations for selecting and interpreting a particular study design.
Fig. 1 (abstract P43). Design & Fidelity Considerations when
measuring impact of malaria RDTs on Morbidity/Mortality compared
to clinical or microscopy diagnosis
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Introduction: Evaluating the impact of diagnostic tests on patients’
health is complex. Due to the multiple steps involved between the
decision to administer a test and effect on patient’s health, a broad
range of outcomes can be measured in studies that evaluate the im-
pact of tests on a patient’s health, and various forms of bias can be
introduced along this pathway. The revised Cochrane risk of bias tool
for randomized studies (RoB 2.0), and that for non-randomised stud-
ies of interventions (ROBINS-I), focus on risk of bias (RoB) assessment
in general but do not point out issues specific to test-treatment inter-
ventions which are a distinct type of complex intervention. We de-
scribe our experience in using the Cochrane RoB tools to investigate
bias in primary studies evaluating the impact of malaria rapid diag-
nostic tests (RDTs) on patient-important outcomes.
Methods: We searched relevant electronic databases and grey litera-
ture and included studies based on predefined inclusion criteria. We
included any primary randomized or non-randomized study that
compared a malaria RDT with one or more other diagnostic tests for
malaria, with an aim of measuring the impact of these tests or strat-
egies on patient-important outcomes. We are currently extracting
data and using the ROB 2.0 tool for randomized studies and the
ROBINS-I for non-randomised studies of interventions to assess RoBof included test treatment studies. Two authors have reviewed the
search output and are currently extracting data and assessing RoB in-
dependently, resolving any disagreements by consensus. We will
present our assessment of RoB across each domain and overall RoB
results for included studies narratively, graphically and by descriptive
statistics.
Results and Discussion: Our data set contains 27 randomised studies
and 22 non-randomised studies. During the conference we will
present our RoB results as well as discuss special considerations for
investigating the RoB in test-treatment studies.
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Background: For a clinician, diagnostic test results alone are not in-
formative unless they are able to estimate the prevalence in their
setting. Diagnostic Test Accuracy (DTA) reviews are facilitating the in-
terpretation of the pooled test performance using a pretest-
probability in a hypothetical cohort. However, it is unknown what
methods are used in DTA reviews to select the target condition’s pre-
test probability.
Objectives: To assess what methods in Cochrane DTA reviews are
used for selecting a pre-test probability to demonstrate a test’s per-
formance using summary sensitivity and/or specificity.
Methods: DTA reviews were selected from the Cochrane Library on
the 2nd of February, 2018. Reviews were eligible when a pooled or
summarized accuracy measure was provided. Data were extracted by
one author and checked by a second author.
Preliminary results: From 81 DTA reviews 59 reviews were eligible
comprising 307 meta-analyses. The following methods for selecting a
pre-test probability were observed: using one point estimate from in-
cluded studies (median [62 analyses], mean [11 analyses]), using a
point estimate and a measure of dispersion (median and range [1
analysis], mean and range [1 analysis], median and lower/upper quar-
tile [3 analyses], median and lower/upper quartile and range [5 ana-
lyses]), using literature (studies reporting prevalence [15 analyses],
WHO suggestion [10 analyses], guideline [4 analyses]), using an as-
sumption (27 analyses), or using an unclear or partially unclear
method (12 analyses).
Preliminary conclusions: This is an ongoing study and updated re-
sults and conclusions will be presented during the conference. No
consensus currently exists on what method should be used to select
a representative pre-test probability. However, it is probably more in-
formative to use multiple pre-test probabilities from data included
for analyses (e.g. a point estimate and a measure of dispersion). Mul-
tiple pre-test probabilities could facilitate the test’s performance in-
terpretation for clinicians in their own practice.
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Overdiagnosis can be defined as a screen-detected cancer that
would have not been detected in the absence of screening. It can be
estimated by the “excess-incidence” in the screened arm of a control
trial but no consensus exists on how exactly this should be done.
Objectives
To determine the potential biases associated with excess-incidence
estimates of overdiagnosis under different scenarios in the screening
and post-screening period.
Methods
Cancer was assumed to progress from an undetectable state, to a
pre-clinical state and finally to a clini- cal state as first described by
Zelen and Feinleib (1969). Screening participants were categorised
on the basis on their state before screening started, whether the dis-
ease progressed to the clinical state during the study, in the period
following screening (relevant cases) or not at all (overdiagnosed).
Standard math- ematical manipulations were used to assess the
sources bias under four different scenarios 1) excess in screening
arm immediately following the end of screening 2) removing the
prevalence round cases
3) Complete follow-up 4) complete follow-up but where trial partici-
pants access screening after the trial finishes.
Results
Excess incidence in the screening at the end of screening (scenario
1) is biased upwards for overdiag- nosis as it includes prevalent and
incident round cases with clinical disease that would have arisen
after screening. Scenario 2 is biased as it fails to include all relevant
and overdiagnosed cancers. Scenario 3 is unbiased but only in the
absence of screening in the period after the end of the trial as per
scenario 4.
Conclusion
Estimates of overdiagnosis using the excess-incidence approach are
subject to bias. Studies that follow- up both cohorts provide un-
biased estimates but only if screening is not accessed in the post-
screening period.
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Background Human chorionic gonadotropin (HCG), α-fetoprotein
(AFP) and lactate dehydrogenase (LDH) are established biomarkers
for testicular cancer prognosis and monitoring. However, there is a
lack of high-quality datasets to provide evidence on their optimal
use in monitoring for recurrent disease.
Methods Routinely collected cohort data from the Oxford University
Hospitals were available for 508 stage I to IV testicular cancer pa-
tients aged 16 to 83 years in whom information from 1,642 imaging
tests and 2,204 tumour marker tests were available. We sought to in-
vestigate the relationship between HCG, AFP and LDH biomarkers
measured during monitoring following curative surgery and testicular
cancer recurrence.
Preliminary Results Between 2004 and 2016, 58 patients (11.4%) ex-
perienced a cancer recurrence. Tumour biomarkers were assessed
mainly at post-chemotherapy (n=376) and during surveillance
(n=917). Median and IQR number of tests during the study period
was 4 (2-6) tests.
Interpretation This large dataset consisting of comprehensive longi-
tudinal follow-up following initial treatment provides an opportunity
to reassess the use of biomarkers in monitoring schemes for testicu-
lar cancer recurrence. Testicular cancers recurred in a small propor-
tion of these patients which suggests many may be undergoing
unnecessary testing.P48
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Background: Shortcomings in study design have been hinted at as
one of the possible causes of failures in translation of discovered bio-
markers into clinical use, but systematic assessments of biomarker
studies are scarce.
Objective: We wanted to document study design features of recently
reported evaluations of biomarkers in ovarian cancer.
Methods: We performed a systematic search in PubMed (MEDLINE)
for recent reports of studies evaluating the clinical performance of
putative biomarkers in ovarian cancer. We extracted data on design
features and study characteristics.
Results: Our search resulted in 1,026 studies; 329 (32%) were found
eligible after screening, of which we evaluated the first 200. Of these,
93 (47%) were single center studies. The median sample size was of
156 (minimum 13 to maximum 50,078). Few studies reported eligibil-
ity criteria (17%), sampling methods (10%) or a sample size justifica-
tion power calculation (3%). Studies often used disjoint groups of
patients, sometimes with extreme phenotypic contrasts; 46 studies
included healthy controls (23%), but only 5 (3%) had exclusively in-
cluded advanced stage cases.
Conclusions: Our findings confirm the presence of suboptimal fea-
tures in recent evaluations of the clinical performance of ovarian can-
cer biomarkers, and the need for a greater awareness of these issues.
Accordingly, this may lead to premature claims about the clinical
value of these markers or the risk of discarding other potential bio-
markers that are urgently needed.
P49
Risk prediction models to aid cancer diagnosis in primary care are
available for use, but to what extent have they been evaluated?
B. Grigore1, R. Lewis2, S. Robinson3, J. Lowe3, J. L. Peters1, A. Spencer4, W.
Hamilton5, S. Price5, A. Medina-Lara4, C. Hyde1
1Exeter Test Group, University of Exeter, UK; 2North Wales Centre for
Primary Care Research, Bangor University, Wrexham, UK; 3PenTAG,
University of Exeter, UK; 4Health Economics Group, University of Exeter,
UK; 5DISCO (Diagnosis of Symptomatic Cancer Optimally), University of
Exeter, UK
Correspondence: C. Hyde
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P49
Background: Prediction models for cancer have been developed into
tools to aid GP decision-making on referral of symptomatic patients
in primary care. This includes mouse-mats, flip-charts, an electronic
system for the Risk Assessment Tool (RAT) and an electronic system
for Qcancer. Although these tools are available to GPs in the UK, an
exploration of their effectiveness, and any validation of the under-
lying prediction models is lacking.
Objectives: To discuss the impact of available evidence on informing
decisions on when prediction models are ready for use in practice,
using examples from our recent systematic review of the clinical ef-
fectives of cancer risk prediction tools to aid decision making in pri-
mary care.
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 21 of 44Methods: We conducted two systematic reviews to assess: 1) the
effectiveness of tools, 2) the validation of the prediction models.
The systematic reviews identified evidence on any tool/prediction
model that met our inclusion criteria, but here we focus on just
the two models (and associated tools) already available to GPs:
Qcancer and RATs. Electronic databases were searched, hits
double-screened, data extracted and risk of bias of included stud-
ies was assessed.
Results: 2 studies investigated the effectiveness of the RATs tool, one
suggesting an increase in rapid referrals and investigations with the
tool, the other suggesting no impact on time to diagnosis compared
to no use of the tool. We found no studies investigating the impact
of the Qcancer tool.
The majority of Qcancer prediction models had been validated exter-
nally, by researchers not involved in the development of the models,
and showed good performance. We did not find any external valid-
ation of the RATs models.
Conclusion: Prediction models for cancer diagnosis in primary care
are available for GPs to use, but neither has been fully evaluated or
validated. We will highlight these gaps and discuss implications for
further work and policy-making.
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Background
Interobserver variability studies estimate variation between results in
which more than one observer interprets the same data. Agreement
in medical imaging interpretation is very important, particularly
whether radiologists agree on the presence or absence of disease in
an imaging dataset. Generally, interobserver variability study results
are shown in a table, using statistical measures such as kappa and
percentage agreement. A table format is however very limiting when
presenting data from multiple observations made in the same pa-
tient especially where data includes disease location.
Objectives
We propose two graphical representations to better encapsulate the
results of complex interobserver variability studies, and improve data
accessibility
Method
We performed a preliminary analysis of data from an interob-
server variably study of small bowel ultrasound in diagnosing
and staging Crohn’s disease, performed as part of a larger diag-
nostic accuracy study (the METRIC trial). A subset of recruited
patients underwent two ultrasound examinations performed
and interpreted by two different radiologists. Radiologists docu-
mented the presence or absence of disease in 10 pre-defined
bowel segments. For the reference standard, an expert consen-
sus panel decided the patient disease status based on all clin-
ical data collated during six months patient follow up. We
developed novel graphical methods to present the interob-
server data.
Results
We will present two different graphical presentations from the ana-
lysis we have completed. One shows where observers agreed and
disagreed on disease location with the consensus panel results. The
other shows agreement and disagreement by disease location separ-
ately for disease positive and disease negative locations. We also give
examples of how this method could be extended to other similar
scenarios.
Conclusion
Graphical representation of interobserver variability could improve
understanding of the results and may provide more informative re-
sults than current summary statistics alone.P51
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Background: MODY is a rare, young-onset, genetic form of dia-
betes. Diagnosing MODY is important to ensure appropriate treat-
ment, but identifying MODY patients is challenging. Diagnostic
testing is expensive, prohibiting universal testing. We developed
the MODY probability calculator (https://www.diabetesgenes.org/
mody-probability-calculator/, >34000 visitors to date), a validated
model that calculates probability of MODY based on clinical fea-
tures, to help clinicians prioritise which patients to refer for diag-
nostic testing.
Objectives/Methods: To assess the use of the MODY calculator in the
real world setting: 1) its performance in a population cohort of pa-
tients diagnosed <30y (n=1407), 2) its utility in clinical referrals sent
to the Exeter molecular genetics diagnostic laboratory for MODY test-
ing (n=1285) between 1/8/14 and 31/12/17.
Results: 1) In the population cohort, 51/1407 (3.6%) were diag-
nosed with MODY; 1293 (45 MODY) had sufficient data to calcu-
late their MODY probability. The model performed well (ROC
AUC=0.9) and showed good calibration (Hosmer-Lemeshow
p=0.24). 39/397 (10%) individuals with probabilities >3.6% had
MODY (87% sensitivity, 69% specificity for this cutoff). 14/21
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 22 of 44(67%) individuals with >75% probability had MODY (31% sensi-
tivity, 99% specificity).
2) In the diagnostic laboratory, 621/1285 (48%) referrals reported use
of the calculator. Referrals that stated they had used the calculator
had a higher pick-up rate of MODY than those that did not (33% v
25%, p=0.002). MODY probability could be calculated on 425/664 re-
ferrals that did not use the calculator. The mean probability was
lower compared with referrals that had used the calculator (16.5% v
42.6%, p<0.001).
Conclusion: The MODY model appears to work well in a population
setting, although analysis was limited by small numbers of MODY pa-
tients. The MODY model is frequently being used prior to sending re-
ferrals for MODY testing. Referrals that use the calculator appear to
be more appropriate, with higher probabilities and a higher pick up
rate of MODY.
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Background
Biological variability (BV) studies aim to measure variability in a bio-
marker between and within individuals. Knowledge of BV allows the
potential for a biomarker to diagnose and monitor disease to be
assessed. Sample sizes for BV studies involve stating numbers of par-
ticipants (n1), observations per participant (n2) and repeat assess-
ments of each observation (n3). Little guidance exists to compute
these values.
Objectives
To assess the precision of estimates at different sample sizes to pro-
vide guidance when planning studies.
Methods
Data were simulated following the model yijk = μ + αi + βij + εijk, with
mean μ, αi  Nð0; σ2GÞ , βij  Nð0; σ2I Þ , εijk  Nð0; σ2AÞ and i = 1, . . ,
n1, j = 1, . . , n2 and k = 1, . . , n3.
Data were simulated varying sample sizes, and random effects
models estimated between-individual (σG), within-individual (σI) and
analytical variation (σA), along with coefficients of variation (CVs),
index of individuality (II) and reference change values (RCV). After
1,000 simulations results were analysed to assess the variation and
accuracy of the estimates.
Results
Increasing participants decreases the range of estimates for σA, σI
and σG; increasing observations decreases the range of σA and σI,
however the range of estimates of σG appeared constant. Increasing
assessments decreases the range of σA with the range of σI and σG
unchanged.
Increasing participants and observations decreases the range of esti-
mates of II and RCV. II was overestimated with few participants. In-
creases in assessments made little change in the range of estimates
of II and RCV.
We have produced a shiny app which allows precision of estimates
to be estimated for given parameter values: https://alicesitch.shi-
nyapps.io/bvs_simulation/.
Conclusion
Sample size decisions for BV studies can use a precision based ap-
proach. Changing numbers of participants, assessments and observa-
tions impacts on the precision of different estimates. Increasing the
number of participants increases precision for all estimates. Simula-
tion of the range of results obtained for a given sample size can
guide planning of studies.P55
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Background:
Systematic and/or random errors in test measurement (collectively
‘measurement uncertainty’) can result from various factors along the
testing pathway, from the time of day a test sample is taken to the
specific platform used for sample analysis. The consequence of this
uncertainty is that any observed test value may differ to the under-
lying ‘true’ target value. Crucially, although this uncertainty can sig-
nificantly affect clinical accuracy and utility, it is rarely considered in
test outcome/impact studies.
Objectives:
To identify current methodology utilized in studies assessing the im-
pact of measurement uncertainty on test outcomes (including clinical
accuracy, clinical utility and cost-effectiveness).
Methods:
A literature review – using MEDLINE, Embase, Web of Science and
Biosis – was used to identify relevant studies published in the last 10
years. Subsequent citation tracking was conducted to identify add-
itional material (published any date). Ongoing data extraction is fo-
cused on identifying study aims, methods (in particular the
components of measurement uncertainty addressed, data sources,
input values and distributional assumptions) and the impact of meas-
urement uncertainty on baseline results.
Results:
Based on interim findings, 45 studies conducted across a range of
settings and indications have been identified. The majority utilize
simulation techniques to explore the impact of measurement bias
(systematic error) and/or imprecision (random error) on clinical accur-
acy or utility. Typically these draw on an ‘error model’ in which bias
is assumed fixed and imprecision normally distributed, e.g.:
Testsimulated ¼ Testtrue þ Testtrue  CV N 0; 1ð Þ½  þ Bias
[where CV = coefficient of variation and N(0,1) = a random draw
from a normal distribution (mean 0, standard deviation 1)]. Both bias
and imprecision have been reported to have a significant impact on
test outcomes within these studies.
Conclusions: Analysis of the final results will enable identification of
key methodological considerations for future applications and re-
search in this field.
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Background:
Clinical guidelines recommend cardiovascular disease (CVD) risk as-
sessment to identify patients who will benefit from lifestyle advice
+/- drug therapy. As current risk tools are not perfect, high-sensitivity
cardiac troponin (hs-cTn), an independent predictor of CVD risk, has
been suggested to improve risk classification for individuals at aver-
age risk.
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 23 of 44Objectives:
To assess whether the clinical performance of risk assessment tools
including hs-cTn supports further investigation for clinical use.
Methods:
We searched MEDLINE to identify studies comparing the perform-
ance of validated CVD risk assessment tools in the adult general
population when adding hs-cTn. We extracted data on troponin, risk
tools, risk categories, risk of bias, and performance measures: discrim-
ination, calibration and reclassification. We summarised the propor-
tion more correctly up (TP) or downgraded (TN), falsely up (FP) or
downgraded (FN) with the addition of hs-cTn. We used the treatment
threshold of 10% 10-year CVD risk to dichotomise low versus high
risk. We calculated the number needed to screen (NNS) to avoid one
additional cardiovascular event. We defined the minimum acceptable
troponin model performance to support further investigation as a
higher TP rate and/or a higher TN rate. We considered the potential
benefits of an additional TP higher than an additional TN. In case of
a trade-off we considered < 10 FP:1 TP acceptable.
Results:
Two studies reported adequate data for our analysis. Both reported a
net improvement in TP and TN rate and modest reduction in NNS
(Table 1). Neither reported troponin model performance in an exter-
nal validation population.
Conclusion:
Two studies provide consistent evidence that including troponin in
two different CVD risk assessment tools improves discrimination of
patients who will/will not develop CVD to guide management at the
risk threshold of 10% 10-year risk. These findings warrant further in-
vestigation, including external validation, for assessment of clinical
benefits, harm and cost-effectiveness.Table 1 (abstract P56). See text for description
Study N Comparator
tool
Index
test
Additional TP FP TN FN NNS
Zeller
2014
12,650
CVD:
853
No CVD:
11,797
ASSIGN
SCORE
variables
ASSIGN
+
hs-cTn
TP 83 FN 42
TN 564 FP 537
Increase in TP rate 41/853
= 4.8% (3.37–6.23)
Increase in TN rate 27/
11797 = 0.2% (0.12–0.28)
TP:FP = 1:6.5
TN:FN = 13.4:1
ASSIGN
218
ASSIGN
+
hs-cTn
198
Blanken-
berg
2016
60,444
CVD:
3178
No CVD:
57,266
ESC SCORE
variables
ESC
SCORE
+
hs-cTn
TP 64 FN 31
TN 461 FP 362
Increase in TP rate 33/
3178 = 1.0% (0.65–1.35)
Increase in TN rate 99/
57266 = 0.2% (0.16–0.24)
TP:FP = 1:5.7
TN:FN = 14.9:1
ESC
SCORE
237
ESC
SCORE
+
hs-cTn
233
Fig. 1 (abstract P57). See text for descriptionP57
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Background:
Spine surgeons need to be able to make evidence-based predictions
on the outcome of surgery. The risks (e.g. complications) and bene-
fits (e.g. pain alleviation) of treatment modalities have to be ad-
equately communicated to their patients. There is a lack of validated
prognostic tools to support spine surgeon and patient decisions in
daily practice. Evidence on predictors for surgical outcomes is avail-
able; however, to date no studies have developed comprehensive
clinical prediction models for spine surgery.Objectives:
To use data from a spine unit collected within a large clinical spine
registry to develop outcome prediction models for patients undergo-
ing surgery after lumber disc herniation.
Methods:
We built lasso regression models to identify relevant predictors and
estimate the parameters for 12-month-outcome prediction of a qual-
ity of life (QoL) score, back and leg pain scores, surgical complica-
tions, and patient satisfaction. A freely available online prognostic
tool was developed to present the predicted outcomes for individual
patients, based on their pre-operative characteristics.
Results:
Data from 1127 patients (mean age 49yrs, 42% female) was used for
model development. Number of previous spine surgeries, insurance
class (private vs general), body-mass index, and preoperative leg pain
were the strongest outcome predictors in most models. The R2 of
the models ranged from 0.16 to 0.21. A preliminary online tool was
programmed for QoL and pain scores (Fig. 1).
Conclusion:
Clinical use of the tool requires further validation. Temporal valid-
ation of the models in the same spine unit is underway. Prospective
collection of additional factors is planned to improve prediction pre-
cision. The main challenges include how and when to update models
in ongoing data collection; generalisability of models to other clinics;
and the limitation of this observational single-arm cohort study,
which does not allow treatment comparisons.P58
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Background: Extrapulmonary tuberculosis (TB in parts of the body
other than the lungs), accounts for around 20% of TB burden world-
wide. In 2013, informed by a non-Cochrane review, WHO recom-
mended Xpert MTB/RIF (Xpert), a rapid nucleic acid amplification
assay, for certain forms of extrapulmonary TB. We performed a
Cochrane review to update the literature and address previously
noted limitations, including the adequacy of culture as reference
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 24 of 44standard, given the paucibacillary nature of extrapulmonary TB. We
provide an example of our approach for TB meningitis.
Methods: To estimate Xpert accuracy, we performed bivariate meta-
analysis (standard model) with culture reference standard and then
fit a latent class meta-analysis (LCMA) model adding parameters for
culture sensitivity and specificity and possible conditional depend-
ence (shared errors) by Xpert and culture. All analyses used Bayesian
inference.
Results: Xpert pooled sensitivity and specificity were 71.1% and
98.0% (standard model) and 63.1% and 99.6% (LCMA). Culture
pooled sensitivity was 68.6% (LCMA). Between-study heterogeneity
in Xpert accuracy decreased after adjustment for heterogeneity in
culture accuracy.
Conclusions: Xpert specificity for TB meningitis was high in all ana-
lyses. Xpert sensitivity was close to that of culture. Adjustment in
Xpert accuracy by LCMA underscored the relatively low sensitivity of
culture and its limitations as a reference standard. Guidance is
needed for summarizing results in the Summary of Findings Table
when the reference standard appears inadequate.Table 1 (abstract P58). Xpert for TB meningitis, 29 studies (3774
specimens, 433 culture-confirmed TB)
Pooled sensitivity
(95% CrI)
Pooled specificity
(95% CrI)
Predicted sensitivity
(95% CrI)
Predicted specificity
(95% CrI)
Xpert accuracy against culture reference, bivariate
71.1% (60.9, 80.4) 98.0% (97.0, 98.8) 71.1% (27.8, 94.8) 98.0% (88.1, 99.7)
Xpert accuracy, latent class
63.2% (53.8, 73.6) 99.6% (98.5, 99.9) 63.1% (39.9, 83.0) 99.6% (98.3, 99.9)
Culture accuracy, latent class
68.6% (59.0, 78.0) 99.3% (98.1, 99.8) 68.5% (44.9, 86.5) 99.3% (97.7, 99.8)P59
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Background
The slope of a plot of observed against estimated outcomes is a use-
ful validation statistic for prediction models, for example when used
as part of a four-part ABCD approach to validation. The slope is often
referred to as a calibration slope. While some authors have used
“calibration” to mean overall calibration, others have reserved the
term “calibration in the large” for overall calibration and used calibra-
tion to mean the accuracy of a prediction rule at a more detailed
level.
Objectives
To review current use and interpretation of the calibration slope, and
compare it to behaviour of the calibration slope in practice.
Methods
1. We searched for papers published in 2016 and 2017 using the cali-
bration slope, and analysed the text to determine whether authors
interpreted it as a measure of calibration, discrimination, or not expli-
citly as either. 2. We studied the behaviour of the calibration slope
first in artificial, examples, and secondly in a re-analysis of a previ-
ously published paper.
Results
In 40 papers using calibration slope, 30 (75%) interpreted it explicitly
as a measure of calibration, 1 interpreted it explicitly as a measure of
discrimination, and 9 as neither. Proof-of-concept examples show
that the calibration slope can remain constant as calibration varies. Ina real example the calibration slope correlates with the c-statistic
(r=0.95; p<0.001) but not calibration-in-the-large (r=0.016, p>0.9).
Conclusions
Although the calibration slope is useful when used in combination
with the intercept, it does not in itself quantify calibration. Many au-
thors inadvertently fail to quantify calibration, by depending on the
calibration slope alone. To prevent misunderstanding, and to pro-
mote the use of better strategies for prediction model validation, the
term “calibration slope” should be retired in favour of a less mislead-
ing alternative.
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Introduction
Working with big(ger) datasets has become an essential part of Life
Sciences research. Due to the existence of a large amount of open
data in this field it has become pivotal to use workflows that support
the data analysis process in a reproducible way. Here we demon-
strate such a workflow. We conclude that the combination of using
literate programming, a self-written R-package to contain all data
and analyses and the use of Git/Github.com greatly enhances repro-
ducibility and the ability to share and publish the project work.
Methods
For our analytics workflow we used the Statistical Programming Lan-
guage R [1]. In this research project, young adult men were re-
quested to cycle four different training protocols on a bike-
ergometer. Rest conditions were used as a control. Before, during
and after exercise blood and saliva were collected from the volun-
teers. Before and after cycling, the volunteers also donated a urine
sample. Biological samples were analyzed for a range of biomarkers
including hormones, cytokines and blood cells. Furthermore, metabo-
lome and the transcriptome analysis were performed. The main re-
search question addressed in this study was whether we can use a
subset of these biomarkers to classify the amount of exercise that
was delivered. To answer this question we analyzed the data with
multi-level statistical models and supervised machine learning.
Results
Due to the data intensive nature of the project and the fact that
many laboratories were involved, R was used in all phases of the ana-
lytics cycle. We implemented the 7 Guerilla Analytics principles
posed by Edna Ridge [2]. These principles help maintaining a link be-
tween the original data and the data in a curated and combined
dataset and ensure reproducibility of analysis and visualizations.
Conclusions
Here we demonstrate that these principles can be implemented in a
R-package, thereby contributing to the reproducibility of this re-
search. We demonstrate our machine-learning experiments to illus-
trate the package.
References
1) R Core Team (2017). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria. URL
https://www.R-project.org/
2) Guerrilla Analytics: A Practical Approach to Working with Data Paperback
– 23 Sep 2014. ISBN-13: 978-0128002186
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 25 of 443) Hadley Wickham (2017). tidyverse: Easily Install and Load the ‘Tidyverse’.
R package version 1.2.1. https://CRAN.R-project.org/package=tidyverse
P61
A systematic review on Diagnostic Test Evaluation Methodology:
The evaluation of diagnostic tests in the absence of gold standard
Chinyereugo Umemneku1, Joy Allen2, Kevin Wilson3, Luke Vale1
1Institute of Health & Society, Newcastle University, Newcastle, UK; 2NIHR
Newcastle In Vitro Diagnostics Co-operative, Newcastle University and
Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK; 3School of
Mathematics, Statistics and Physics, Newcastle University, Newcastle, UK
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P61
Background:
Diagnostic accuracy studies typically estimate the performance of a
new clinical test by comparing it’s results with the best available ref-
erence standard. Provided the reference standard used is, or is as-
sumed to be, a “gold standard” and is applicable to all participants of
the study, the seemingly unbiased estimates of the accuracy mea-
sures, such as sensitivity and specificity can be obtained using the
conventional method. However, if the reference standard is imperfect
or cannot be applied to all study participants; other methods can be
used to estimate diagnostic accuracy to overcome these
shortcomings.
Aim:
This systematic review seeks to describe methods that have been
proposed or applied in evaluations of diagnostic tests in the absence
of gold standard. It aims to update the review undertaken 11 years
ago by Rutjes et al. (2007) entitled “Evaluation of diagnostic tests
when there is no gold standard. A review of methods”.
Methodology:
A peer reviewed protocol was developed and registered in PROS-
PERO. Databases related to medical research such as Medline,
Embase, Scopus, Web of Knowledge, HMIC, Wiley Online database,
CINAHL, PROSPERO were searched. Articles that met the eligibility cri-
teria were included in the review. A PRISMA chart was used to depict
the number of articles searched and included in the review.
Data Analysis:
Data will be collected from eligible articles using the data collection
form developed by the authors. Data extracted from the articles will
include: the method applied or proposed, important assumptions,
case-studies used, and the strengths and weaknesses of each
method. The information obtained will be synthesised qualitatively.
Conclusion:
The review will describe novel methods using case studies, articulate
the strengths and weaknesses of the methods and develop recom-
mendations for their use.
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Background
Heart failure (HF) is a major public health problem with rising preva-
lence, especially in elderly. Survival rates for advanced HF patients are
worse than those for breast or prostate cancer. Two decades of bio-
marker research highlighted the prognostic ability of certain markers,
and informed the development of new or updated prognostic models.Despite numerous published models and NICE’s recognition of
the need for prognosis information, no risk stratification models
have been adequately established, nor has the quality of the
models and the evidence they present being systematically
brought together and tested.
Objectives
We hypothesise that HF–related biomarkers may offer an added
value to the traditional prognostic factors for HF clinical outcomes,
independent of other present co-morbidities. We aim to test this hy-
pothesis through a systematic reviews series assessing the evidence
of HF prognostic models using novel meta-analysis (MA) method-
ology and relevant critical appraisal tools.
Methods
We follow Cochrane methodology. Published search filters were com-
bined for a sensitive literature search. Prognostic models including at
least one HF-related biomarker were eligible. Independent pairs of
co-authors carried out screening and data extraction. Based on the
CHARMS and PROBAST checklists we considered model development
studies with and without external validation in independent data,
and model updating studies. MA will be carried out using recently
published novel methodology.
Results
Searches yielded over 40,000 titles, highlighting the need for tighter,
updated prognostic search filters. A pilot screening of 10% of these
(ie 4000) returned only a 2% for full text screening, with an ultimate
estimate of 150 included models for evaluation.
Conclusions
This is a complex time constrained project with potential to advise
on future HF prognostic model design; contribute to improved HF
clinical management; apply recently developed MA methodology for
combining prognostic model data, and inform the project for devel-
oping Cochrane methodology standards of prognostic model
reviews.
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Planned systematic reviews
SR1: Characteristics and methodological quality of prognostic models in HF
SR2: Characteristics and methodological quality of studies exploring the
added prognostic value of the biomarkers
SR3: Model validation quality and prediction accuracy of prognostic models
in HF
SR4: Meta-analysis of the performance of prognostic models externally
validated
SR5: Impact assessments of prognostic models in HF
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Background
The Revised Cardiac Risk Index (RCRI) is a predictive tool to estimate
the postoperative probability of major adverse cardiac events (MACE)
in patients undergoing noncardiac surgery. Although commonly
used, external validation reveals only moderate performance.
Addition of biomarker(s) to the RCRI seems promising.
Objective
In this systematic review, we aim to quantify the added predictive
value of several biomarkers to the RCRI, using and developing new
methodology for systematic reviews of incremental value studies.
Methods
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 26 of 44A systematic search has been conducted in Web of Science for arti-
cles citing the original development paper. Inclusion criteria are ori-
ginal research papers reporting external validation of the RCRI with
model updating using biomarkers. Updating of the model consists of
adding one or multiple biomarkers to the RCRI. The predictive per-
formance of the extended RCRI model is compared to the RCRI
alone.
Results
The original RCRI publication has been cited 1,383 times. After
screening, 74 articles externally validated the RCRI and of these, 23
articles reported the added value of a biomarker(s) to the RCRI. Blood
based biomarkers, including NT-proBNP, BNP, CRP and troponin,
were the most frequently studied (n=16). In most articles, only one
biomarker was added to the RCRI (n=16). External validation of the
RCRI reported in the selected articles resulted in moderate discrimin-
ation (c-statistics; median [range]: 0.65 [0.58 - 0.79]), which improved
after addition of a biomarker (c-statistics 0.73 [0.59 - 0.88], Table 1).
All models improved with addition of a biomarker. CRP and NT-
proBNP/BNP yielded the largest increments in terms of model per-
formance (Δ c-statistics were 0.12 and 0.13 respectively). Pooled re-
sults will be available at the presentation.
Conclusion
Addition of biomarker(s) to the RCRI resulted in better preoperative
risk prediction. Meta-analysis of incremental value studies requires
novel methodology.Table 1 (abstract P63). Predictive performance using c-statistic for RCRI
alone versus RCRI models with biomarkers
# of selected
articles
RCRI RCRI +
biomarker
Blood based biomarker
NT-proBNP/BNP 6 0.61 [0.59-0.68] 0.74 [0.65-0.77]
Troponin 4 0.66 [0.59-0.72] 0.72 [0.67-0.83]
CRP 3 0.63 [0.59-0.67] 0.75[0.69-0.77]
Other 3 0.69 [0.58-0.79] 0.61 [0.59-0.79]
Imaging based biomarker
Coronary computed
tomographic angiography
3 0.63 [0.62-0.65] 0.73 [0.66-0.77]
Other 3 0.65 [0.57-0.78] 0.70 [0.65-0.79]P64
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Background
Diagnosis in primary care can be challenging; many early symptoms
of cancer are non-specific and low risk. Clinicians may use ‘routine’
blood tests in such patients for reassurance, assuming negative tests
represent absence of disease. Diagnosis is a two-step process; the
first Bayesian step is the clinicians’ decision to perform a test; the
second is the test result itself.
Objectives
To determine incidence of cancer in primary care populations with
inflammatory marker (C-reactive protein, ESR and plasma viscosity),
or platelet tests using primary care records.
Methods
Two independent prospective cohort studies of 40,000 and
200,000 UK Primary Care patients using Clinical Practice Research
Datalink (CPRD). The primary outcome for both studies was 1-
year cancer incidence.Results
For context, NICE recommends urgent cancer investigations or refer-
ral for patients with cancer risk of 3% or above. For inflammatory
markers those with positive tests had a 1-year cancer incidence (PPV)
of 2.80%, test negatives 1.28% and untested 0.84%, the last of these
being marginally below expected figures from National Cancer Regis-
try and Analysis Service (NCRAS). For platelets those with positive
tests had 1-year cancer incidence of 7.84%, test negatives 2.82%, and
population baseline from NCRAS 1.41%. For both tests a significant
gender difference was demonstrated; men with normal inflammatory
markers have 1.75% 1-year cancer incidence, compared to 0.98% for
women; men with normal platelet count have 4.1% 1-year cancer in-
cidence, compared to 2.2% in women.
Conclusions
These results demonstrate a clear Bayesian phenomenon in selection
of patients for simple testing in primary care. The selection process
identifies a group at significantly higher risk, with this additional risk
not wholly eliminated by a negative result. This phenomenon dem-
onstrates the need for clinical vigilance with negative test results. We
anticipate a similar phenomenon occurs with other test results, and
may occur in secondary care.
P65
PROBAST – A risk of bias tool for prediction modelling studies
R. F. Wolff1, K. G. M. Moons2,3, R. D. Riley4, P. F. Whiting5,6, M. Westwood1,
G. S. Collins7, J. B. Reitsma2,3, J. Kleijnen1,8, S. Mallett9
1Kleijnen Systematic Reviews Ltd, York, United Kingdom; 2Julius Center
for Health Sciences and Primary Care, University Medical Center Utrecht,
Utrecht, The Netherlands; 3Cochrane Netherlands, University Medical
Center Utrecht, Utrecht, The Netherlands; 4Research Institute for Primary
Care and Health Sciences, Keele University, Keele, Staffordshire, United
Kingdom; 5School of Social and Community Medicine, University of
Bristol, Bristol, United Kingdom; 6The National Institute for Health
Research Collaboration for Leadership in Applied Health Research and
Care West at University Hospitals, Bristol NHS Foundation Trust, Bristol,
United Kingdom; 7Centre for Statistics in Medicine, Nuffield Department
of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University
of Oxford, Oxford, United Kingdom; 8School for Public Health and
Primary Care (CAPHRI) Maastricht University, Maastricht, The Netherlands;
9Institute of Applied Health Sciences, University of Birmingham, United
Kingdom
Correspondence: R. F. Wolff
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P65
Background: Quality assessment of included studies is a crucial step
in any systematic review (SR). Review and synthesis of prediction
modelling studies is an evolving area and a tool facilitating quality
assessment for prognostic and diagnostic prediction modelling stud-
ies is needed.
Objectives: To introduce PROBAST, a tool for assessing the risk of bias
and applicability of prediction modelling studies in a SR.
Methods: A Delphi process, involving 40 experts in the field of pre-
diction research, was used until agreement on the content of the
final tool was reached. Existing initiatives in the field of prediction re-
search such as the REMARK and TRIPOD reporting guidelines formed
part of the evidence base for the tool development. The scope of
PROBAST was determined with consideration of existing tools, such
as QUIPS and QUADAS‑2.
Results: After six rounds of the Delphi procedure, a final tool was de-
veloped which utilises a domain-based structure supported by signal-
ling questions similar to QUADAS‑2. PROBAST assesses the risk of
bias and applicability of prediction modelling studies. Risk of bias re-
fers to any shortcomings in the study design, conduct or analysis
leading to systematically distorted estimates of predictive perform-
ance or an inadequate model to address the research question. The
predictive performance is typically evaluated using calibration, dis-
crimination and sometimes classification measures. Assessment of
applicability examines whether the prediction model development or
validation study matches the systematic review question in terms of
the target population, predictors, or outcomes of interest
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 27 of 44PROBAST comprises four domains (Participant selection; Predictors; Out-
come; Analysis) and 20 signalling questions grouped within these domains.
Conclusion: PROBAST can be used to assess the quality of prediction
modelling studies included in a SR. The presentation will give an
overview of the development process and introduce the final tool.
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Background It is well understood that a test or multivariable predic-
tion model should be validated in multiple studies or centers before
introduction to clinical practice. Recently, meta-analytic techniques
have been proposed to summarize discrimination and calibration
across populations. Although measures of clinical utility are advo-
cated to go beyond discrimination and calibration and into account
the harms of false positives and benefits of true positives, methods
that recognize heterogeneity do not yet exist.
Objectives To propose a suitable meta-analysis method for Net Bene-
fit (NB).
Methods A Bayesian trivariate random-effects meta-analysis of sensi-
tivity, specificity, and prevalence. Across a range of harm-to-benefit
ratios, this provides a summary measure of NB, a prediction interval,
and an estimate of the probability that the test/model is clinically
useful in a new setting. In addition, statistics can be calculated condi-
tional on the known prevalence in a new setting. The proposed
methods are illustrated by two case studies: one on the meta-
analysis of studies on ear thermometry to diagnose fever, and one
on the validation of the LR2 risk model for the diagnosis of ovarian
cancer in a multicenter dataset.
Results In both case studies the clinical utility of the test/model was
heterogeneous, limiting usefulness in practice. Clinical utility
depended on the harm-to-benefit ratio dictated by the clinical con-
text. E.g., the probability of usefulness of ear thermometer in a new
setting varied from nearly 0 to >.9, depending on the harm-to-
benefit ratio. For a given harm-to-benefit ratio, added clinical useful-
ness of the model over default strategies ‘treat all’ and ‘treat none’
varied with prevalence, reflecting miscalibration and spectrum bias.
E.g., the probability of utility of LR2 was .75 in a new setting with
prevalence .35 and 1.00 in a new setting with prevalence .15.
Conclusion Heterogeneity in clinical utility should be assessed before
a test/model is routinely implemented.
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Background: Recent years have witnessed the development of
Health Technology Assessment (HTA) methods for use by developers
and public bodies to assess potential cost-effectiveness at the early
stages of device development.
Objectives: 1) To provide an overview of current methods used; and
2) To identify issues and needs for future key methodological devel-
opment in early health technology assessment.Methods: Rapid review methods will be used to identify published
methods papers and literature reviews related to early HTA by
searching relevant electronic databases including MEDLINE, EMBASE,
The National Health Services Economic evaluation database (NHS
EED), the Cochrane library, and Econlit. Contacts will be made with
research groups who have published early HTA work in both the UK
and the Netherlands to identify relevant unpublished papers. Inclu-
sion criteria will be research and review papers that report early HTA
methods, as well as commentaries describing or discussing early HTA
methods, published in English.
The overview will extract data from papers to answer the below
questions:
1. How ‘early HTA’ was defined, especially what stage of device
development means ‘early’?
2. What are the proposed aims of early HTA?
3. What frameworks have been developed to evaluate early HTA?
4. What methods have been proposed/identified/applied in early
HTA?
5. What are the extant methodological issues in need of further
examination and development?
Results: The literature review is currently ongoing and results will be
ready at the time of conference in early July 2018. Initial search
found four literature reviews, and five methodology development pa-
pers. Preliminary findings include that papers discussed differences
between early and late stage HTA and associated methods applied.
These include headroom analysis, decision analytical modelling, sen-
sitivity analysis, Bayesian modelling, and probabilistic risk analysis.
Discussions were limited on methods to identify clinical care
pathways.
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Background
Prediction models for people with type 2 diabetes are often static
models, using only a person’s risk profile at a single time point. As
the cumulative amount of HbA1c (‘glycemic burden’) was found to
be associated with various diabetes outcomes, including information
on dynamics of HbA1c over time may increase the accuracy of pre-
dicting nephropathy over using a single HbA1c measurement only.
Objectives
To compare a ’static’ prediction model based on Cox regression ana-
lysis to a joint modelling approach for the prediction of diabetic ne-
phropathy, using a single or repeated HbA1c measurements
respectively.
Methods
This study included 7616 people with type 2 diabetes from the
Hoorn Diabetes Care System cohort, who were followed annually
from 1998 onwards. Nephropathy was defined as macroalbuminuria.
For the Cox regression only the baseline HbA1c value was taken into
account. For the joint model, repeated measurements of HbA1c were
used. In both models, baseline variables sex, age, diabetes duration,
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 28 of 44systolic blood pressure, BMI, triglycerides and total cholesterol were
included as other predictors. All variables were standardized before
joint model analysis. Results were expressed in terms of hazard ratios
and Harrell’s C statistic for discrimination.
Results
In total, 394 (5.3%) people developed nephropathy during a mean
follow-up of 6.3 (±4.9) years. In both models, sex, age, systolic blood
pressure, BMI, triglycerides and HbA1c were independent predictors
of diabetic nephropathy. Specifically, the hazard ratio for HbA1c was
equal to 1.14 (95% CI 1.07-1.22) in the Cox model and 1.84 (1.61-
2.10) using joint modelling. The joint model showed an AUC of 0.70
and a prediction error of 0.06. The discriminative ability of the Cox
model was slightly lower, with an AUC of 0.68.
Conclusion
Based on model discrimination, including repeated HbA1c measure-
ments seems to predict the risk of diabetic nephropathy slightly bet-
ter compared to the Cox model.
P69
Adaptive designs for diagnostic accuracy studies
Antonia Zapf
Department of Medical Biometry and Epidemiology, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
Diagnostic and Prognostic Research 2018, 2(Suppl 1):P69
Planning a clinical trial is always tainted with uncertainty. On the one
hand for the sample size calculation assumptions are necessary,
which prove to be false during the ongoing trial. On the other hand
it can be of interest to modify design aspects during the study
(whereas these modifications have to be pre-specified in the study
protocol). While for treatment studies there are plenty of methods
for such adaptive study designs, for diagnostic accuracy studies there
are almost no methods for adaptive designs. Accordingly, no diag-
nostic accuracy trials with an adaptive design could be found in the
literature. Since diagnostic trials fail very often because of wrong as-
sumptions, it is highly necessary to develop methods for adaptive
designs in the field of diagnostic trials. An example is the recently
published diagnostic trial from Waugh et al. [1].
In the talk I will present different settings where adaptations would
be helpful in diagnostic trials and I will distinguish between blinded
and unblinded sample size re-estimation. Furthermore, drawing from
the literature on adaptive designs in the field of treatment studies, I
will show where existing methods can be transferred to diagnostic
trials [2,3]. Regarding the remaining blind spots, I will present exist-
ing and new methods specific for diagnostic trials [4].
References
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Statisticians tend to provide, clinicians to communicate, and patients
to understand prognosis in terms of a single number, as if it were a
date in a calendar. Patients find information about prognosis difficult
to understand and of little use for decision making.
Objectives
To develop an evidence-based approach to improving the utility of
prognostic information.
Methods
We synthesized key literature on presenting and using prognosis in-
formation, and developed a prototype for visualizing prognostic sta-
tistics and confronting the inherent uncertainties, using ovarian
cancer survival data from SEER as an example.
Results
Quantifying prognosis
Can be expressed as:
1. Life expectancy (e.g. one year).
2. Chance of living one year (e.g. 50%).
Uses for prognostic statistics:
1. For groups: e.g. to compare outcomes and choose the most likely
outcome.
2. For individuals: supporting an approach of planning for the worst,
hoping for the best, and acting on the best bet.
Quantifying uncertainty
Uncertainty in prognosis is due to:
1. Stochastic processes – can be quantified by confidence intervals
and inter-centile ranges, and visualized with histograms and prob-
ability distributions.
2. Changing clinical information (for example surviving one year in-
creases your probability of survival) – can be quantified and visual-
ized by conditional prognosis plots. Prognostic information intended
for individuals seldom includes information on uncertainties. Some
statisticians have recommended routinely providing inter-centile
ranges, and others conditional prognosis plots. However, reporting
guidelines for prognosis studies have not adopted these
recommendations.
Conclusion
We propose a programme of work:
1. Studies of how patients would like the uncertainties in prognosis
to be presented, and how they would use the information.
2. Updates of reporting guidelines for prognosis studies to include in-
formation on uncertainties and conditional prognosis (where
practical).
3. Development of a database-building toolkit for conditions with
prognostic information, to help patients and physicians.P71
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Background
For a prognostic model to be used to guide treatment decisions, pre-
dictions should represent a patient’s outcome risk if they were to re-
main untreated. Clinical data used for model development typically
include some individuals who were treated during follow-up. Ignor-
ing this can lead to a model that underestimates the true untreated
outcome risk.
Objectives
To compare methods to account for treatment use during follow-up
when developing a prognostic model.
Diagnostic and Prognostic Research 2018, 2(Suppl 1):12 Page 29 of 44Methods
A prognostic (Cox) model to predict 5-year mortality risk without
using selective beta-blockers was developed using the electronic
health record data of 1905 patients (585 deaths). We compared 5
methods to account for selective-beta blocker use during follow-up:
(i) excluding treated individuals, (ii) censoring treated individuals, (iii)
inverse probability of censoring weighting after censoring treated in-
dividuals, (iv) including treatment as a binary covariate in the model
and (v) including treatment use as a time-varying covariate in the
model. The comparisons were repeated in a highly-treated patient
subset and with a simplified prognostic model.
Results
324 (17%) patients began using selective beta-blockers during fol-
low-up. The coefficients of the prediction models varied according to
each modelling method. Excluding treated individuals resulted in a
model that provided, on average, slightly higher predictions com-
pared to a model that ignored treatment. However, these differences
did not translate to substantial differences in predictive performance
(c-statistic, calibration slope, Brier score) in any of the analyses.
Conclusion
Treatment hardly affected predictive performance in our case study.
Despite theoretical advantages of certain methods to account for
treatment use, in practice the actual benefit of applying these
methods may be small. Further case studies and simulations are
needed to investigate when it is necessary to take into account the
effect of treatment when developing a prognostic model.
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Objectives
To systematically review the evidence and assess the relative per-
formance of clinical prediction models in the evaluation of patients
with early rheumatoid arthritis.
Methods
A systematic review of studies describing the development, external
validation and impact of eligible clinical prediction models was
conducted in accordance with PRISMA guidelines and current best
practice for undertaking prognostic reviews. Data on predictive per-
formance were described in a narrative synthesis, presented separ-
ately for internal and external validation studies. Evidence synthesis
using meta-analysis was considered for external validation studies.
Results
Twenty-two model development studies and one combined develop-
ment/external validation study reporting 39 clinical prediction
models for three relevant outcomes were included. Five external val-
idation studies evaluating eight models for radiographic joint dam-
age were also included. C statistics for radiographic progression
outcomes (different definitions) ranged between 0.63 and 0.87 (n=8)
and between 0.78 and 0.82 for Health Assessment Questionnaire
(HAQ) outcomes (n=2). For models that had been externally vali-
dated, predictive performance varied considerably, suggesting unex-
plained heterogeneity in the populations in which the models are
being tested. Three models (ASPIRE-CRP, ASPIRE-ESR, BeSt) were vali-
dated using the same outcome definition in two external popula-
tions. The random effects meta-analysis suggested the most
favourable performance across external validations was for BeSt (C
statistic 0.72, 95% CI: 0.20, 0.96). However, for all models, there is
substantial uncertainty in the expected predictive performance in a
new sample of patients, indicating that we cannot be confident that
the performance of the models is better than would be expected by
chance.Conclusion
Meta-analysis was limited by the small number of external validation
studies and the results do not provide a definitive conclusion about
performance of the models in future studies. Reasons for the hetero-
geneity in performance could not be explored. Uncertainty remains
over the optimal prediction model(s) for use in clinical practice.
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Some fifty years ago, Schwartz and Lelouch discussed how thera-
peutic trials can try to resolve two very different problems. The first
set of so-called explanatory trials aims at understanding a treatment,
seeking to discover whether it causes benefit and/or if difference ex-
ists between two treatments. The second set of pragmatic trials aims
at decision-making: these trials try to answer the question which
treatment is preferable under usual clinical circumstances. The differ-
ence affects the definition of the treatments, the choice of study par-
ticipants, and the way in which the treatments are compared. The
PRagmatic Explanatory Continuum Indicator Summary (PRECIS-2) was
later developed to further clarify this distinction.
Diagnostic accuracy studies evaluate the performance of a test in
correctly identifying those with and without the correct target condi-
tion, by comparing index test results with those of the clinical refer-
ence standard.
We argue that, like therapeutic trials, diagnostic accuracy studies can
also try to answer two different questions. One set, explanatory accur-
acy studie, aims at understanding how different conditions affect the
distribution of test results. A second set, aimed at decision-making,
evaluates the consequences of relying on the test’s results for clinical
management: pragmatic accuracy studies. Confusingly, both types of
trials often present their findings in terms of sensitivity and specifi-
city or the area under the ROC curve.
The difference between pragmatic and explanatory diagnostic accur-
acy studies cannot be simplified as a matter of design-related bias
and applicability. It has implications for the definition of the index
test, the eligibility criteria and recruitment of study participants, the
choice of the study outcomes, the analysis of results, and the inter-
pretation. We present the building blocks for PRECIS-DTA, at tool that
can be used in the design, analysis, interpretation, reporting and
communication of diagnostic accuracy studies.
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Background: Meta-epidemiological studies have shown that short-
comings in study design can lead to biased estimates of treatment
effects and diagnostic test accuracy. It remains unclear to what ex-
tent study characteristics may affect estimates of prognostic model
performance.
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the results of external validation studies of prognostic models.
Methods: We searched electronic databases for systematic reviews of
prognostic models. Reviews from non-overlapping clinical fields were
selected if they reported common performance measures (concord-
ance (c)-statistic or ratio of observed over expected number of
events (OE ratio)) from ten or more validations of the same model.
From the included validation studies we extracted study design fea-
tures, population characteristics, methods of predictor and outcome
assessment, and the aforementioned performance measures. Ran-
dom effects meta-regression was used to quantify the association be-
tween study characteristics and model performance.
Results: We included ten reviews, describing a total of 224 valida-
tions. Associations between study characteristics and model perform-
ance were heterogeneous across reviews. C-statistics were most
associated with population characteristics and measurement of pre-
dictors and outcomes, e.g. validation in a continent different from
the development study resulted in a higher c-statistic, compared to
validation in the same continent (difference in logit c-statistic 0.10
[95% CI 0.04, 0.16]), and validations with eligibility criteria compar-
able to the development study were associated with higher c-
statistics compared to narrower criteria (difference in logit c-statistic
0.21 [95% CI 0.07, 0.35]). Using a case-control design was associated
with higher OE ratios, compared to using cohort data (difference in
log OE ratio 0.97 [95% CI 0.38, 1.55]).
Conclusion: Variation in performance of prognostic models appears
mainly associated with variation in case-mix, study design, and predictor
and outcome measurement methods. Researchers validating prognostic
models should carefully take these study characteristics into account
when interpreting the achieved performance of prognostic models.
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Background: It is widely recommended that any developed - diag-
nostic or prognostic - prediction model is externally validated in
terms of its predictive performance measured by calibration and dis-
crimination. When multiple validations have been performed, a sys-
tematic review followed by a formal meta-analysis helps to
summarize overall performance across multiple settings, and reveals
under which circumstances the model performs suboptimal (alterna-
tive poorer) and may need adjustment.
Objectives: To discuss how to undertake meta-analysis of the per-
formance of prediction models with either a binary or a time-to-
event outcome.
Methods: We address how to deal with incomplete availability of
study-specific results (performance estimates and their precision),
and how to produce summary estimates of the c-statistic, the obser-
ved:expected ratio and the calibration slope. Furthermore, we discuss
the implementation of frequentist and Bayesian meta-analysis
methods, and propose novel empirically based prior distributions to
improve estimation of between-study heterogeneity in small sam-
ples. Finally, we illustrate all methods using two examples: meta-
analysis of the predictive performance of EuroSCORE II and of the
Framingham Risk Score. All examples and meta-analysis models have
been implemented in our newly developed R package metamisc.
Results: Information on model discrimination and calibration was
often incomplete, but could be restored for most studies. Although
the proposed meta-analysis models yielded similar summary esti-
mates, the Bayesian approach allows for more accurate estimation ofbetween-study heterogeneity when few studies are included in the
meta-analysis.
Conclusion: Meta-analysis of prediction models is a feasible strategy
despite the complex nature of corresponding studies. As developed
prediction models are being validated increasingly often, and as the
reporting quality is steadily improving, we anticipate that evidence
synthesis of prediction model studies will become more common-
place in the near future. The R package metamisc is designed to fa-
cilitate this endeavor, and will be updated as new methods become
available.
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Background: Cochrane has been publishing Diagnostic Test Accuracy
(DTA) reviews for 10 years, and close to publishing their 100th DTA
review. The methods and reporting of Cochrane DTA reviews were
designed to ensure they address patient management questions by
providing evidence summaries suitable for incorporation in clinical
guidelines.
Objectives: To assess the extent to which Cochrane DTA reviews
have been incorporated in clinical guidelines; identify which guide-
line developers and topics are most likely to make use of Cochrane
DTA evidence; note key features of reviews most cited.
Methods: Cochrane UK tracks citations of Cochrane Reviews in clin-
ical guidelines published worldwide by searching online, open access
sources of accredited guidelines (free at the point of use) for the
word “Cochrane”. We analysed citations of Cochrane DTA reviews,
identified up until the end of March 2018, by guideline developer,
topic and key characteristics of reviews, including: (a) focus on com-
parative accuracy questions; (b) number of studies included; (c) clear
positioning of the test in the clinical pathway; (d) presentation of
consequences of testing; (e) clear clinical recommendations.
Results: As of 2nd March 2018, 41 of 92 published DTA reviews
(45%) from 17 Cochrane Review Groups have been used to inform
56 clinical guidelines, 14 have been used in more than one guideline.
DTA reviews have been cited in UK guidelines (30 times, 19 by NICE);
German (8); US (5); WHO (4); Canada (3); Europe (3); World, Australia
and Belgian (2); Ireland, Poland, Spain, India, South Africa, Latin
America, Italy, and France (1).
Conclusions: Many Cochrane DTA reviews are impacting on clinical
guidelines. Cochrane DTA reviews are resource intensive and it is im-
portant that the topics chosen, and methods used optimise
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Background
In April 2018 WHO held the first meeting of the Strategic Advisory
Group of Experts in In Vitro Diagnostics (SAGE IVD) to define the
Table 1 (abstract O6). Change in HbA1c in mmol/mol at 6 months
(with 95% confidence intervals) per standard deviation greater baseline
value of predictor. A negative value represents a reduction
(improvement) in HbA1c
a) SGLT-inhibitors b) DPP4-inhibitors
Baseline
HbA1c
eGFR HDL Baseline
HbA1c
BMI Triglycerides
CPRD -9.5 (-9.8;-
9.0)
-1.75 (-2.2;-
1.3)
2.2
(1.5;2.9)
-8.4 (-8.6;-
8.2)
1.0
(0.8;1.1)
0.9 (0.6;1.1)
Trials -5.8 (-6.1;-
5.5)
-1 (-1.3;0.7) 0.6
(0.3;0.8)
-4.7 (-5.5;-
3.9)
0.4
(0.0;0.9)
0.5 (0.1;1.0)
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Diagnostics (EDL). The EDL intends to provide evidence-based guid-
ance, and set a reference for the development of national lists of es-
sential IVDs. The initial EDL meeting looked at existing WHO
guideline recommendations for tests for TB, HIV, hepatitis B and C,
malaria and syphilis.
Objective
To identify key methodological challenges for WHO evidence review
methods to support the EDL process.
Methods
Full reports for tests for TB, HIV, hepatitis B and C, malaria and syph-
ilis were identified and methods and reporting compared against a
20-item framework developed from PRISMA-DTA, the Cochrane DTA
Handbook, GRADE guidance and discussions of experts. One of three
DTA experts reviewed guidance and noted both good practice and
notable differences.
Results
Nine evaluations for TB, 8 for hepatitis B and C, 1 each for malaria
and syphilis, and 16 for HIV were identified and reviewed. Methods
and themes identified where harmonisation is required include:
abandoning the PICO question to one suited to test accuracy; em-
phasis on comparative accuracy; the value of protocols; the role of
indirect evidence; assessment of risk of bias and applicability; use of
existing systematic review evidence; statistical methods; reporting
consequences of test use for accuracy evidence; evaluation of evi-
dence beyond accuracy; grading and assessing the strength of evi-
dence. We will illustrate key issues with examples.
Discussion
Standardisation of WHO evidence review methods for tests is needed
to support development of the EDL. We will report the progress of
the SAGE IVD in deciding on a methodological approach for, and re-
port on the key outstanding methodological areas which require fur-
ther development and research.
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Background: Individual participant data from randomised trials are
increasingly available for researchers to answer secondary research
questions. Repositories include YODA and Clinical Study Data Re-
quest. There may be great potential to harness these data to evalu-
ate potential precision medicine approaches. We propose a
framework involving discovery analysis in routine clinical data
followed by validation in trials, and apply this to evaluate a precision
medicine approach to predict good response to type 2 diabetes drug
therapy.
Methods: Discovery analysis: We included 30,511 patients with type
2 diabetes starting either a SGLT-2 inhibitor(SGLT2i) or DPP4-
inhibitor(DPP4i) in routine clinical data from the UK (CPRD). Associa-
tions between clinical measures and glycaemic response (6 month
HbA1c–baseline HbA1c) to each drug were evaluated individually
using linear regression. Validation: From YODA, we pooled individual
participant data from 6 randomised drug efficacy trials of SGLT2i, 2
had a DPP4i comparator arm (n=3929). In the pooled trial data we
tested clinically relevant associations observed in CPRD using multi-
variable three-level (trial-patient-study visit) linear mixed-effects
models.
Results: In CPRD, we identified key clinical features associated with
differential response to the two drugs (Table 1). Higher baseline
HbA1c was associated with greater response (a reduction in HbA1c)
to both drugs, but to a greater extent with SGLT2i. Greater SGLT2iresponse was associated with higher eGFR and lower HDL. Greater
DPP4i response was associated with lower triglycerides and lower
BMI. All associations replicated in trial data (Table 1).
Conclusion: The availability of individual trial data from repositories
such as YODA and Clinical Study Data Request provides a tremen-
dous opportunity to evaluate potential precision medicine ap-
proaches. Discovery in routine data followed by validation in trial
data provides a principled framework to utilise trial data without
data-mining. Our findings using this framework suggest there may
be potential to develop prediction models for drug response in type
2 diabetes.O7
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Background: The availability of individual participant data (IPD) from
multiple sources allows the external validation of a prediction model
across multiple settings and populations. When applying an existing
prediction model in a new population it is likely that it will suffer
from some over or under fitting, potentially causing poor predictive
performance. However, rather than discarding the model outright, it
may be possible to modify components of the model to improve its
performance using model recalibration methods. Here, we consider
how IPD meta-analysis methods can be used to compare and select
the most appropriate recalibration method, or whether a completely
new model is warranted in a particular setting.
Methods: We examine four methods for recalibrating an existing lo-
gistic prediction model in cardiovascular disease across multiple cen-
tres: (i) re-estimation of the intercept, (ii) adjustment of the linear
predictor as a whole (calibration slope), (iii) adjustment of individual
heterogeneous predictor effects, and finally (iv) re-estimation of all
model parameters. We use multivariate IPD meta-analysis to jointly
synthesise calibration and discrimination performance across centres
for each of the methods. The most appropriate recalibration method
can then be evaluated based on the joint probability of achieving a
given model performance in a new setting, using this to rank recali-
bration methods.
Results: We present a new Stata package allowing estimation of the
joint probability of achieving a set level of model performance in a
new setting for each recalibration method, therefore easily identify-
ing the method with the highest probability. We show that the best
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bration as opposed to developing new models unnecessarily when
the probability of improved performance through recalibration is
high.
Conclusions: Multivariate meta-analysis allows quantification of the
most appropriate recalibration methods to improve the performance
of an existing prediction model in new settings.
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Background: Many non-invasive diagnostic imaging methods
are available to manage secondary care of patients presenting
with stable (suspected cardiac) chest pain, though confirma-
tory diagnosis is often by invasive coronary angiography (ICA).
The 2010 NICE guideline for managing chest pain (CG95) rec-
ommended risk-stratified management of these patients in
Rapid Access Chest Pain clinics. Stratification was by com-
puted pre-test likelihood (PTL) of coronary artery disease
(CAD), based on the Duke Clinical Risk (1993) PTL model: pa-
tients with PTL>60% were recommended for immediate ICA;
patients with PTL 10-60% were recommended for non-invasive
imaging with abnormal findings being a “gatekeeper” to ICA
referral. Concerns were raised that this PTL-stratified manage-
ment would lead to an excess of patients undergoing ICA
when CAD was not present.
Objectives: The UK CE-MARC2 trial (2016) aimed to determine the
difference in rates of unnecessary (CAD absent) ICA within 12 months
between a NICE CG95 (2010) based risk-stratified management algo-
rithm, or a uniform non-invasive imaging “gatekeeping” strategy ei-
ther by Cardiac Magnetic Resonance (CMR) or Myocardial Perfusion
Scintigraphy (MPS).
Methods: 3-arm, parallel group, six-centre Randomised Controlled Trial,
481:481:240 patients were allocated to CMR:MPS:CG95. Endpoints were
(primary) unnecessary angiography 12 months post-randomisation and
(secondary) major adverse cardiovascular event (MACE) within 12 and
36 months and CAD detection within 12 months.
Results: Unnecessary angiography rates in the non-invasive-first
strategies were one quarter that in the risk-based CG95 strategy
(7.5 and 7.1% vs 28.8%). This difference (21.5%) was due to PTL
over-estimation by the Duke model in CG95 patients: only 28%
of CG95 mandatory ICA (PTL>60%) detected CAD. There were no
significant differences in rates of CAD detection or MACE at 12
months.
Conclusion: CE-MARC2 warns that while risk-stratification is a reason-
able approach to management, the clinical benefits may be lost if
the underlying risk model is poorly calibrated: contemporary external
validation is essential.O9
An interactive web application to aid diagnostic test accuracy
meta-analysis
Suzanne Freeman1, Clareece Kerby2, Nicola Cooper1 and Alex Sutton1
1NIHR Complex Reviews Support Unit, Biostatistics Research Group,
Department of Health Sciences, University of Leicester, Leicester, UK;
2Biostatistics Research Group, Department of Health Sciences, University
of Leicester, Leicester, UK
Correspondence: Suzanne Freeman
Diagnostic and Prognostic Research 2018, 2(Suppl 1):O9
Background: A meta-analysis of diagnostic test accuracy (DTA) stud-
ies synthesises multiple studies to evaluate the performance of a
diagnostic test. Often there is variation between studies surrounding
the threshold used to determine whether a patient is healthy. DTA
meta-analysis can be performed using either the bivariate or hier-
archical summary receiver operating curve (ROC) models, and the re-
sults presented either around a mean point or as a summary ROC
curve. Conventionally, summary ROC curves are published as static
graphs. An alternative is to consider interactive graphs which can
allow multiple perspectives to be displayed, information to be tai-
lored to the user’s preference and provide a useful tool to aid sensi-
tivity analyses.
Objectives: (i) To develop a freely-available web-based “point and
click” interactive tool which allows users to input their data and con-
duct meta-analyses, including sensitivity analyses. (ii) To illustrate the
benefits of the interactive application using an existing DTA meta-
analysis (1).
Methods: To create our online freely-available interactive application
we used the existing R packages mada and Shiny to analyse the data
and create an interactive user interface.
Results: An interactive online application was created for conducting
meta-analysis of DTA studies. The user interface was designed to be
easy to navigate. Benefits include the ability for users to enter their
own data, exploration of a range of different threshold values and
what this means in terms of true and false positive rates, and the
ability to conduct sensitivity analyses.
Conclusion: We built a freely-available interactive online application,
available at https://crsu.shinyapps.io/dta_ma/, which meta-analyses
DTA studies, plots the summary ROC curve and allows for sensitivity
analyses to be conducted in a timely manner. This application will
allow a wide range of users to carry out specialised analyses without
needing software beyond an internet browser.
References
1. Kriston L et al Ann Intern Med 2008;149:879
O10
Methodologies for evaluation of clinical tests in their early stages
of development
S. Graziadio1, A. J. Allen2, K. Wilson3
1NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle upon Tyne
Hospitals Foundation Trust, Newcastle upon Tyne, UK; 2NIHR Newcastle
In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon
Tyne, UK; 3Mathematics, Statistics and Physics, Newcastle University
Diagnostic and Prognostic Research 2018, 2(Suppl 1):O10
Background
In early diagnostic test evaluations the potential benefits of the intro-
duction of a new technology in the current healthcare system are
assessed in the challenging situation of limited empirical data. These
evaluations provide tools to evaluate which technologies should pro-
gress to the next stage of evaluation.
Fig. 1 (abstract O11). Study designs for diagnostic accuracy studies
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We aim to identify new approaches within the Bayesian framework
for care pathway analysis for early test evaluations.
Methods
In this study a diagnostic test for patients suffering from
Chronic Obstructive Pulmonary Disease (COPD) was evaluated
with Bayesian networks, which provide a compact visualization
of probabilistic dependencies and interdependencies. The struc-
ture of the network was inferred from the care pathway, a sche-
matic representation of the journey of a patient in the
healthcare system. After the network was inferred and reduced
with arc reversal techniques, it was populated using expert
judgement elicitation. The Bayesian network was then queried
to evaluate whether the introduction of the test could reduce
unnecessary hospital admissions. Uncertainty analyses were
used to determine credible intervals for the comparison be-
tween the current and new pathway, and to identify influential
parameters of the decision problem.
Results
We found that the adoption of the diagnostic test had the po-
tential to reduce the number of missed COPD exacerbations of
symptoms that could lead to late hospital admissions, and of
unnecessary visits to A&E. The model inputs that most influ-
enced the posterior distribution were identified as the probabil-
ity that a patient would go to A&E if an exacerbation was
suspected, the probability that the healthcare professionals in
primary care refer patients to the hospital, and the sensitivity of
the test.
Conclusion
These results are useful to companies to inform the choice of
the target population, of potential early adopters and the iden-
tification of the technological focus to guide development of
the test.
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Background
The methodological challenge in low prevalence situations is
that a classical diagnostic accuracy design requires large
sample sizes to estimate sensitivity with adequate precision.
Reducing sample sizes without introducing risk of bias is
challenging.Objectives
To collate and discuss designs and methods of diagnostic accuracy
studies which can be used in low prevalence situations.
Methods
We performed a literature search in four electronic databases
(Cochrane Library, Embase, Medline, Web of Science), used backward
citation tracking, and invited experts to identify studies with relevant
designs or methods. Two reviewers independently included studies
describing a study design or method for estimating diagnostic accur-
acy in a low prevalence situation. Studies on prognostic tests or im-
pact studies of diagnostic tests were excluded. During a one-day
meeting with the expert group, the list of methods was discussed
and recommendations were formulated.
Results
We identified four designs for single binary tests, one design for mul-
tiple conditions, and one design for comparing two tests without verifi-
cation of double negatives. The four designs for single binary tests
were stratification design, two-phase design, case-control design, and
nested case-control design. Figure 1 shows the classical diagnostic ac-
curacy design and the six designs that could reduce the total number
of patients or the number of patients undergoing the reference stand-
ard or index test. Table 1 provides a ranking of the most suitable de-
signs including potential pitfalls. Additionally, we formulate
recommendations for sample size calculation, logistic regression ana-
lysis in small datasets, use of big datasets and population weighting.
Conclusion
This overview of designs and methods could help researchers design
a diagnostic accuracy study in low prevalence situations. Researchers
may consider this in future studies and understand the advantages
and limitations.
Table 1 (abstract O11). Summary of design ranking in different
methodological situations
Stratification
design
Two-
phase
design
Case-
control
design
Nested
case-
control
design
Comprehensive
diagnostic
study design
Comparing
two tests
without
verification
of double
negatives
Methodological situation:
Population
Different
strata in
patient
population
Only option
Index test
Stored
data
available
on index
test
Only
option
Costly or
invasive
index test
Second
option
Third
option
First
option
Two index
tests
Third
option
Second
option
First
option
Multiple
index tests
Only option
Reference standard
Costly or
invasive
reference
standard
Third
option
First
option
Second
option
Target condition
Extremely
low
prevalence
(<0.001%)
Only
option
Multiple
target
conditions
Only option
Risk of Bias
QUADAS-2
Higher risk
of bias if
there is
more
difference
between
prevalence
strata
Higher
risk of
bias if the
selection of
reference
standard
is not
random
Higher risk
of bias if
cases or
controls
do not
represent
the same
population
Higher
risk of
bias if
the
selection
of index
test is
not
random
Higher risk of
bias if there is
no reference
panel to
determine
the diagnosis
Higher risk
of bias if
both index
tests are
not
blinded
from each
other
If there were more than one design applicable, the first three options were ranked on suitability
based on sample size and risk of bias. Other designs might be possible as well in
specific situations.
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Background: Diagnosis of lung cancer frequently occurs in its
later stages. Low-dose computed tomography (LDCT) could detect
lung cancer early but like all screening there is risk of
overdiagnosis.
Objective: To estimate the effectiveness of LDCT in high risk popula-
tions to inform the UK National Screening Committee.
Methods: A systematic review of randomised controlled trials (RCTs)
was conducted, comparing LDCT screening programmes with usual
care (no screening) or other imaging screening programmes (such aschest X-ray). Meta-analyses were performed. We focus on the find-
ings relating to overdiagnosis in this presentation.
Results: Twelve RCTs were included in the review, only three of
which currently contribute evidence on lung cancer numbers. Com-
pared with controls (usual care/best available care), LDCT screening
was associated with a statistically significant increase (pooled RR
1.38, 95% CI 1.02 to 1.86) with at least five years follow-up. Our find-
ings further demonstrated a shift due to LDCT screening on the
stage distribution towards earlier stages for detection of lung can-
cers. LDCT screening was associated with a statistically significant in-
crease in early stage (I and II) cancer detection (pooled RR 1.73, 95%
CI 1.27 to 2.37) with a corresponding statistically significant decrease
in late stage (III and IV) cancer. There was a statistically significant re-
duction in the absolute risk of late stage lung cancer, indicating that
there is an element of actual stage shift (pooled RR 0.85, 95% CI 0.73
to 1.00).
Conclusion: There was clear evidence of overdiagnosis, but the de-
gree to which we could quantify this was constrained. We will reflect
on whether we could improve on this in future up-dates of the sys-
tematic review and what data would be required in order to do this.
We will also consider how claims from screening advocates that
overdiagnosis can be easily mitigated by improved radiological tech-
niques can be tested.O13
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Background: Although there are a variety of approaches to evaluat-
ing the accuracy of tests, the terms used to describe these ap-
proaches are limited and lack standardization. In parallel with
ongoing research to develop a more rational and informative set of
study design labels for test accuracy, we are investigating the use
made of study design labels in the diagnostic guidance of one na-
tional policy making body, NICE.
Objectives: To describe the range of study design terms used and to
investigate whether different weight is given to different study de-
signs in the final guidance.
Methods: We will extend the approach used in past analysis of the
methodological features of NICE guidance. All NICE Diagnostics Guid-
ance and underpinning summaries of the evidence will be interro-
gated, focusing on tests used for diagnosis. We will abstract data on:
the policy question addressed; the accuracy evidence found and the
inclusion criteria for the reviews of it; the study design terms used to
describe the evidence; the quality assessment process; whether the
evidence was sub-divided by different study designs; and whether
the final guidance recognized any differences in study design. Ana-
lysis will be qualitative.
Results: Earlier investigations suggest little use of study design terms
to recognize differences in accuracy study design. We will extend
these initial observations.
Conclusion: The lack of a series of study design terms which quickly
and reliably convey study designs which have different levels of in-
trinsic bias is an important barrier to good reporting of accuracy
studies. However it is also critical for good secondary research. With-
out such terms all accuracy studies may be considered equal with
quality assessment tools being the only means to recognize varying
threat to validity arising from different study designs. These tools
have not usually been designed for this purpose.
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Background
When there is no one single perfect reference standard to which an index
test can be compared in a diagnostic test accuracy (DTA) study, an alter-
native option can be to have a panel of clinicians evaluate the presence
of disease based on a combination of tests. Expert panels are typically
forced to make black and white decisions, ignoring any uncertainty that
may still be present in individual patients. This dichotomization of disease
can lead to biased DTA estimates of the test of interest (index test).
Objective
To demonstrate how forcing dichotomization of disease can lead to
biased diagnostic accuracy estimates of an index test.
Methods
In this simulation study the following parameters were varied: the
number and accuracy of tests used in the panel, the accuracy of the
index test, and disease prevalence. For each possible combination of
test results the probability of obtaining that test pattern and corre-
sponding likelihood of disease were calculated. Individuals with test
patterns with a disease probability of >0.5 were classified diseased,
or otherwise as non-diseased. This dichotomization was used to cal-
culate bias in index test DTA estimates.
Results
The amount of bias in index test DTA estimates depends on the
magnitude and combination of number and accuracy of component
tests, disease prevalence, as well as the true value of the index test.
The Fig. 1 shows the bias of index test sensitivity and specificity in
our base-case scenario (four component tests, with sensitivity and
specificity of 70%, and a prevalence of 0.2). Although prevalence
does not affect reference standard performance, it can have signifi-
cant and unpredictable impact on bias in index test DTA estimates.
Conclusion
Forcing dichotomization of probabilistic estimates of a reference
standard can lead to significantly biased estimates of index test sen-
sitivity and specificity. Researchers should consider implementing
probability estimates when working with expert panels.Fig. 1 (abstract O14). Bias in estimates of index test sensitivity and
specificity for a range of true values as result of dichotomization of
the reference standardO15
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Background:
Since the most appropriate threshold at which to operate a test is
usually a key clinical question, there is a need to move beyond
standard meta-analysis methods which: (i) do not provide summary
estimates of accuracy at each threshold and (ii) can only synthesise a
single pair of sensitivity and specificity from each study, despite stud-
ies often reporting data at more than one threshold. Some more ad-
vanced methods have recently been proposed, notably that of
Steinhauser et al (2016), but a limitation is the need to pre-specify
the distributional form of test results in the diseased and disease-free
populations.
Objectives:
To develop a meta-analysis model which (i) provides estimates of the
sensitivity and specificity of a test across all thresholds, (ii) makes use
of all available data, (iii) makes less restrictive assumptions about the
distributional form of test results than recently proposed approaches,
(iv) works directly with count data (numbers of patients with test
results above each threshold), rather than requiring normal
approximations.
Methods:
We describe a multivariate meta-analysis model for count data, that
can take any number of counts from each study and explicitly quan-
tifies how accuracy depends on threshold. The model allows for a
flexible range of distributions of underlying test results by estimating
a transformation parameter as part of the model. We fit the model in
Bayesian statistical software such as WinBUGS or JAGS.
Results:
We demonstrate with a case study meta-analysis, quantifying the ac-
curacy of B type natriuretic peptide in diagnosing acute heart failure.
Conclusion:
Our new meta-analysis model estimates the sensitivity and specificity
of a continuous test at all thresholds, and does not require the ana-
lyst to pre-specify the distributional form of underlying test results.
Further, the model does not require normal approximations, which
can perform poorly in the presence of small counts.
O16
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Background
Prediction models are often developed on a single data set, therefore
performance in different settings and populations is frequently poor.
If so, one may validate and update or tailor the model to the valid-
ation situation at hand, but this is not always feasible if performance
is too poor and the validation data set is too small. We propose to
use measures of generalizability in the development process of pre-
diction models already, in the case of using large clustered develop-
ment data sets.
Objectives
The aim of our methodology is to produce developed models that are
more robust when applied across different settings and populations, and
to prevent the need for constant validation and tailoring to local settings.
Fig. 1 (abstract O18). See text for description
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We apply several measures, namely existing measures such as the
coefficient of variation, GINI’s mean difference and the pooled vari-
ance as well as newly developed measures, in a variable selection
procedure for developing a prediction model until it attains optimal
performance within and across different settings and populations.
Results
We illustrate our proposed approach by modelling 30-day mortality
of patients in critical care units. Using independent validation sam-
ples for the developed models, we assess the Brier score, calibration
slope and c-statistic of the models. We perform a meta-analysis of
these performance statistics to assess generalizability of the predic-
tion model (e.g. as quantified by the between-cluster heterogeneity).
Conclusion
Our new approaches can be used for prediction model development
in large clustered data sets, to develop better generalizable predic-
tion models.
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Background
After impact evaluation has demonstrated the added benefits of
a new test, actual implementation is crucial to achieve these ben-
efits in practice. Although point-of-care (POC) tests commonly
offer benefits in terms of low turn-around-time, and improved
patient’s satisfaction and health outcomes, only few are imple-
mented in practice.
Objectives
This study aims to identify which criteria are, in general, important in
the decision to implement and use a POC test, and to determine
their weight. Two POC tests available for use in Dutch general prac-
tices (i.e. CRP and HbA1c) serve as case studies.
Methods
Relevant criteria were identified based on a literature review and
semi-structured interviews with twelve experts in the field. Subse-
quently, the criteria were clustered in four groups (i.e. user,
organization, clinical value, and socio-political context). The relative
importance of each criterion was determined using Multi-Criteria De-
cision Analysis (MCDA), with the Analytic Hierarchy Process. During
this group session, priorities of ten experts regarding both POC tests
were elicited, as compared with central laboratory testing.
Results
Of 20 criteria in four clusters, the test’s clinical utility, its technical
performance, and risks associated with the test-based treatment de-
cision were considered most important for using a POC test, with
relative weights of 22.2%, 12.6% and 8.5%, respectively. Overall, the
experts preferred POC CRP over its laboratory equivalent, whereas
they did not prefer POC HbA1c. This difference was mainly explained
by their strong preference for POC CRP regarding the subcriterion
clinical utility.
Conclusion
MCDA can be a valuable tool to identify criteria, and their relative im-
pact, affecting test implementation in practice. Insight into the cri-
teria and their weights identified in the case studies may facilitate
implementation of existing POC tests. Having experts score new POC
tests on these criteria provides developers with recommendations on
how to increase the probability of successful implementation.O18
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Background
Model-based impact analyses are typically useful for assessing the
cost-effectiveness of a limited, pre-defined, number of alternative
testing strategies, none of which may be optimal.
Objectives
To illustrate how using a meta-model allows optimization of test use/
impact, in a case study on screening for colorectal cancer, while ac-
counting for colonoscopy capacity constraints.
Methods
Screening strategies were defined by starting age, screening interval,
number of screening rounds, and FIT test positivity threshold
(>50,000 unique strategies). A limited sample of predefined strategies
(n=150) was evaluated with the validated ASCCA simulation model
to identify the best screening strategy therein, in terms of life-years
gained (LYG), compared with no screening. A Gaussian Process meta-
model was fitted to this sample and discrete evolutionary program-
ming was applied to determine the optimal screening strategy (GP-
DEP approach) for different colonoscopy capacity constraints. Sample
size of predefined strategies was varied (n=25-200) to assess GP-DEP
performance using bootstrapping, brute force exhaustive search, and
comparison with ASCCA outcomes.
Results
GP-DEP provided stable optimal screening strategies for sample sizes
n>=100. Compared with ASCCA, LYG and costs of the optimal strat-
egies from GP-DEP were accurate and slightly too high, respectively.
However, performance ranking of strategies was similar according to
ASCCA and GP-DEP. GP‑DEP resulted in better screening strategies
(higher number of LYG) compared to just evaluating predefined
strategies, for different capacity constraints (see Fig. 1). For sample
size n=100 average predicted benefit of the optimal strategy identi-
fied by GP-DEP compared to the best strategy identified by ASCCA
equalled 0.028 LYG (95%CI 0.013-0.043) per individual.
Conclusion
It is feasible and beneficial to optimize rather than evaluate test im-
pact. Optimization using a meta-model of the ASCCA model allowed
fast identification of the optimal screening strategy, even when con-
straints apply, and outperformed the best screening strategy as typ-
ically identified from a limited sample of predefined strategies.
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Background: The credibility of comparative diagnostic accuracy re-
views threatened by the lack of studies directly comparing the accur-
acy of one test versus that of another test. If a single test performs
well in one study, and a second test less so in a different study, it is
unclear whether this difference in performance is genuine, or due to
differences in study design. Comparative accuracy reviews based on
single test studies therefore lead to invalid conclusions and there is
not yet a solution to this problem.
Objectives: To investigate whether a causality research approach
provide opportunities to adjust for confounding in comparative ac-
curacy research.
Methods: When answering the question which test has the highest
accuracy, then a causal inference framework may become relevant. If
test A was investigated in a different patient population than test B,
then differences between the tests may be caused by population ra-
ther than test characteristics. As confounding may play a role in the
comparison between tests, the concepts from causality research may
be used to remove bias in these meta-analyses. A pilot study was
done with a seven-step approach for choosing covariates from a di-
rected acyclic graph to adjust for.
Results: We re-analyzed a systematic review of over 150 studies on
rapid tests for influenza, 10 studies evaluated the Directigen test and
21 evaluated the Quickvue test. Before adjustment, the sensitivity of
the Directigen test was 77% and that of the Quickvie test 49%; after
adjustment, the sensitivity was 79% for Directigen and 69% for
Quickvue. However, this is only one small pilot and there is no gold
standard for unconfounded comparisons in this review.
Conclusion: This presentation explains why and how causal inference
may have a place in (comparative) diagnostic test accuracy research
and will discuss the pitfalls when translating these concepts to diag-
nostic accuracy.
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Background: In studies of diagnostic test accuracy of ordinal tests, re-
sults are sometimes only reported for cutoff thresholds that generate
desired results in a given study (e.g., high combined sensitivity and
specificity). When combining results in meta-analyses, selective cutoff
reporting may result in biased accuracy estimates. One way to over-
come this bias is via individual participant data meta-analysis
(IPDMA). Another approach is to use published results, but to model
missing cutoff data using statistical techniques.
Objectives: To compare IPDMA of data from all studies and cutoffs to
three approaches for estimating diagnostic test accuracy using pub-
lished data in the context of missing cutoff data: (1) conventional
meta-analysis using bivariate random-effects meta-analysis, andmodeling missing cutoff data using multiple cutoff models devel-
oped by (2) Steinhauser et al. and (3) Jones et al.
Methods: We analyzed data collected for an IPDMA of Patient Health
Questionnaire-9 depression screening tool accuracy. We compared
sensitivity and specificity estimates from conventional meta-analysis
of published results, the two modelling approaches, and IPDMA. The
modeling approaches were applied to the published dataset blind to
IPDMA results.
Results: 15,020 participants (1,972 cases) from 45 studies were ana-
lyzed. All methods produced similar specificity estimates. Compared
to IPDMA, conventional bivariate meta-analysis underestimated sensi-
tivity for cutoffs <10 and overestimated sensitivity for cutoffs >10
(mean absolute difference: 6%). For both modeling approaches, sen-
sitivity was slightly underestimated for all cutoffs (mean underestima-
tion: 2%).
Conclusion: IPDMAs are the gold standard for evidence synthesis, but
are labor intensive. In the context of missing cutoff data, applying
modeling approaches to published data is more efficient than IPDMA
and produces accuracy estimates that more closely resemble IPDMA
than not modeling. However, applying modeling approaches to pub-
lished data resulted in a slight underestimation of sensitivity in our
case study and precludes the possibility of assessing accuracy in par-
ticipant subgroups.
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Background: Transportability of prediction models can be hampered
when predictors are measured differently at development and (exter-
nal) validation. This may occur, for instance, when predictors are
measured using different cut-off points or when tests are produced
by different manufacturers. While such heterogeneity in predictor
measurement across development and validation seems very com-
mon, little is known about the impact it may have on the perform-
ance of prediction models at external validation.
Objectives: To define effects of predictor measurement heterogen-
eity on external performance of prediction models, by taking a meas-
urement error perspective to describe measurement heterogeneity.
Methods: Using analytical and simulation approaches, we examined
the external predictive performance of a clinical prediction model
under different scenarios of heterogeneous predictor measurement,
using a well-known taxonomy of measurement error models to recre-
ate heterogeneity in measurement procedures.
Results: Heterogeneity in measurements of predictors can have a
large impact on the external predictive performance of a prediction
model, often leading to worse but possibly to improved external pre-
dictive performance. This may result in either overfitted or under-
fitted prediction models, to extents that the prediction model may
no longer be clinically useful. Furthermore, our simulation study
showed that commonly recommended shrinkage strategies (e.g.
Ridge regression) may both improve or worsen the impact of hetero-
geneity in measurement procedures on the external predictive
performance.
Conclusion: Our work highlights measurement heterogeneity as
an important explanation of unanticipated out-of-sample perform-
ance of clinical prediction models, as dissimilarities in the mea-
surements of tests and markers between development and
validation deteriorate the actual predictive power of the model at
external validation.
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Background: As 1.8 million of the 10.4 million people with new TB
cases die each year, timely diagnosis and treatment initiation is critical.
However, traditional diagnostic methods, such as culture or smear mi-
croscopy, are slow or low in sensitivity; more modern techniques, such
as sequencing or GeneXpert MTB/RIF, are inaccessible to populations at
greatest risk of contracting TB. The WHO has proposed biomarkers as
the bases for needed new diagnostic assays to detect active TB.
Objectives: To assemble the existing biomarkers and biosignatures
used to identify active TB and evaluate the quality and level of evi-
dence around them.
Methods: In collaboration with FIND and in relation to WHO’s high-
priority Target Product Profiles (TPPs), we conducted a systematic re-
view of biomarkers for the detection of active TB. A comprehensive
search term was composed and used in multiple scientific databases.
Results: Initially, 6543 publications from 2010 to 2016 were identified. After
deduplication, 3970 records were screened by title and abstract. Finally, 374
publications fulfilled the inclusion criteria. Types of biomarkers identified in-
cluded antibodies, cytokines, metabolic activity markers, Mycobacterial anti-
genic proteins, RNA, and volatile organic compounds. Only 51% of studies
reported a culture-based reference standard and diagnostic performance
data beyond p-values. Risk of bias due to study design was generally high.
Only 8% of studies were considered high-quality and met TPP mini-
mum criteria for sensitivity and specificity. Frequently, publications
repeated the findings of other discovery-phase studies without mov-
ing the biomarker to further developmental stages.
Conclusions: Validation studies that incorporate intended diagnostic
use-cases are needed. The extracted data are currently being used
by FIND as the foundation of a dynamic database where biomarker
data and developmental status will be presented. Ultimately, this
database will enable developers and researchers to populate the TB
biomarker pipeline, accelerating diagnostic test development.Fig. 1 (abstract O22). Risk of bias; percentages are of total
included studiesO23
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their set-up and management that differ from randomised controlled
trials (RCTs) of interventions. Birmingham Clinical Trials Unit (BCTU)
manages and provides statistical support for a wide range of test
evaluation trials as well as RCTs of interventions.
Objective: To identify unique challenges in the set-up and manage-
ment of trials of tests in order to improve future trial design and
management.
Method: Within the CTU we set up a working group to review ex-
perience of ten trials of tests for diagnosis, staging, screening and
monitoring. We identified themes where particular challenges were
noted which did not occur or were different for RCTs of
interventions.
Results: The ten studies covered bladder overactivity, chronic kidney
disease, thyroid nodules, neoplasia in chronic colitis, maternal group
B streptococcal colonisation, causes of pelvic pain, ovarian cancer, ex-
tent and activity of Crohn’s disease, staging of lung & colorectal can-
cer, and staging and management in ovarian cancer. Tests included:
PET-CT, CT, MRI and ultrasound, biomarker measurements, develop-
ment and evaluation of biomarker panels and near patient and la-
boratory based IVDs.
Ten topics were identified that appear unique or to have higher im-
pact on test studies than intervention RCTs including specific issues
in: ethics and governance, patient selection, recruitment, uncertainty
of diagnostic results, test processes and pathways, sample prepar-
ation and measurements, reference standards, follow up, adverse ef-
fects and diagnostic impact.
Discussion: While some of these themes also occur in RCTs, the rela-
tive importance or risks differ from those in test studies. These
themes will be presented in more depth using examples from the
ten trials and strategies used to resolve or minimise the impact in
specific trials will be reviewed. Identifying challenges in these studies
is important to enhance the design and conduct of future test
studies.
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Background
The incorporation of early Health Technology Assessment (HTA)
might be beneficial for Medical Device (MD) industry; however, evi-
dence that industry is conducting early HTA remains scarce.
Objectives
This study aims to develop an evidence-based framework to under-
stand whether, and to which extent, early HTA might drive product
success of small and large enterprises (SEs and LEs).
Methods
This research encompassed four stages (Fig. 1). We conducted a key-
informant process (stage 1) where 25 international experts identified
a list of emergent HTA themes that they believed were important to
company success. A sample of 22 European and US selected com-
panies then reached consensus on a list of key themes through a ro-
bust Delphi process (stage 2). Finally, in stage 3, we constructed the
‘MEDKET’ checklist for SEs and LEs by defining and prioritizing key
themes using comments and ratings from stage 1 and 2.
Results
We found out that SEs perceived success as business continuity,
whereas LEs identified success as large-scale utilization and patient/
user value. ‘MEDKET’ for SEs and for LEs included, respectively, 21
and 15 items, with 9 overlapping themes. In both groups, success
was driven by three item categories: (i) R&D processes (e.g. starting
time of assessment activities); (ii) device outcome-measures (e.g.
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business model) and of MD market (e.g. being an incumbent in the
reference market segment).
Conclusion
Our results showed that early HTA plays a pivotal role in MD industry
success and it could have different implications based on enterprises
size. On one hand, the adoption of early HTA in SEs setting could be
vital for the companies’ survival. On the other hand, investing the
proper amount of funds in early HTA by LEs can increase the overall
R&D efficiency; however, the allocation of additional funds after a
certain threshold does not guarantee MD success.Fig. 1 (abstract O24). Study outline
Fig. 1 (abstract O25). See text for descriptionO25
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Background: This study compares former obstetric care as usual (Ex-
pect I) with risk-dependent care using a prediction tool (Expect II).
The Expect I study externally validated 39 prediction models using
data of 2,614 women prospectively included from 2013 to 2015. Clin-
ically useful models were embedded in a web-based prediction tool.
Additionally, risk-dependent care paths were developed, resulting in
antenatal care tailored to the outcomes of individual risk assess-
ments. Risk-dependent care was embraced by a consortium of ob-
stetric healthcare professionals in the Dutch province of Limburg.
Methods: Women receiving risk-dependent care are being enrolled in a pro-
spective multicenter cohort (Expect II). Primary outcomes are adherence of
healthcare professionals and compliance of women to key recommendations;
e.g. adequate calcium intake in all women (Expect I, adequate calcium intake
in 34% of women) and low-dose aspirin treatment to women at increased
risk of preeclampsia (Expect I, actual use in the high-risk group: 1.5%).
Preliminary results: Tenmonths after introduction our prediction tool is being
used in an estimated 24-40% of pregnant women (Fig. 1). Currently, 435 women
have been enrolled. Recommendations regarding calcium intake were discussed
with 351 women (81%), of which 285 (81%) reported the intention to comply. In
case of an elevated preeclampsia risk (n=223) preventive aspirin treatment was
discussed with 180 women (76%), of which 52 (29%) intended to comply.
Conclusion: The preliminary results indicate risk-dependent care has
been implemented by a reasonable proportion of healthcare profes-
sionals. Furthermore, usage of the prediction tool appears to increase
recommendation of preventive interventions. Implementing new
guidelines asks an additional effort of caregivers, especially if imple-
mentation requires a reorganization of their routine and includes novel
strategies such as a prediction tool. Future research should focus on
barriers that hamper the adherence of healthcare professionals to risk-
dependent care and on reasons for non-compliance of women.
Keywords:
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Background:
The United States Food and Drug Administration (FDA) granted ac-
celerated approval for the check-point inhibitor, pembrolizumab, to
treat patients with locally-advanced or metastatic solid tumours of
any origin that are mismatch-repair deficient (dMMR) or microsatel-
lite instability-high who have progressed after prior treatment and
have no satisfactory alternative treatment options. The FDA has re-
ferred to this indication as “tissue/site agnostic”, whereas in Australia,
the Medical Services Advisory Committee has referred to this as a
“pan-tumour” approach.
This pan-tumour approach is new for health technology assessment
groups. To date, evaluation of the (cost-)effectiveness and safety of
both the targeted cancer drug and the companion diagnostic test
have been assessed for specific biomarkers, such as HER2, EGFR, and
BRAF, in patients with common cancer types, such as melanoma,
breast, colorectal or lung cancer. For these applications, the evidence
base would generally include at least one randomised trial compar-
ing the effectiveness of the targeted treatment in either the test-
positive population (including falsely-positive patients), or the whole
cohort (including patients with either false-positive or false-negative
results).
Objective:
To provide guidance on the evidence needed to evaluate pan-
tumour applications.
Method:
We examined the effectiveness of dMMR testing for access to pem-
brolizumab in tumours of diverse origin.
Results and conclusion:
Pan-tumour populations include rare tumour types that are sup-
ported by minimal clinical evidence, such as single arm studies.
There are differences in the standard of care for tumours arising from
diverse sites of origin, and there are limited data for determining the
accuracy of the diagnostic test in these different tumour types. Fur-
thermore, the prevalence of dMMR was highly variable across tumour
types, greatly affecting the clinical validity (PPV and/or NPV) of the
test. We caution that the proportion of patients with false-positive
and false-negative test results – and consequent adverse treatment
outcomes - per cancer must be considered.
Fig. 1 (abstract O28). See text for description
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Background: Network meta-analyses have extensively been used to
compare the effectiveness of multiple interventions for healthcare policy
and decision-making. However, methods for evaluating the performance
of multiple diagnostic tests are less established. In a decision-making con-
text, we are often interested in comparing and ranking the performance
of multiple diagnostic tests, at varying levels of test thresholds.
Objective: To develop a framework for evaluating multiple diagnostic
tests, at varying test thresholds in one simultaneous analysis.
Methods: Motivated by an example of cognitive impairment diagnosis
following stroke, we synthesized data from 13 studies assessing the ef-
ficiency of two diagnostic tests: Mini-Mental State Examination (MMSE)
and Montreal Cognitive Assessment (MoCA), at two test thresholds:
MMSE <25/30 and <27/30, and MoCA <22/30 and <26/30. Using Mar-
kov Chain Monte Carlo (MCMC) methods, we fitted a bivariate network
meta-analysis model, accounting for the correlations between multiple
test accuracy measures from the same study, and incorporating con-
straints on increasing test thresholds assuming that higher test thresh-
olds had an increased sensitivity but decreased specificity.
Results: We developed and successfully fitted a model comparing
multiple tests/threshold combinations while imposing threshold con-
straints. Applying constraints on increasing test thresholds reduced
the within-study variability and increased the precision in estimates
of sensitivity and specificity. Using this model, we found that MoCA
at threshold <26/30 appeared to have the best true positive rate (es-
timated sensitivity: 0.98; 95% credible interval (CrI): 0.94,0.99), whilst
MMSE at threshold <25/30 appeared to have the best true negative
rate (estimated specificity: 0.84, 95%CrI: 0.79,0.88).
Conclusions: In a health technology assessment setting, there is an
increasing need to compare the efficiency of multiple diagnostics
tests. The combined analysis of multiple tests at multiple thresholds
allowed for more rigorous comparisons between competing diagnos-
tics tests for decision-making.
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Background: Diagnostic and prognostic prediction models often per-
form poorly when externally validated. The reasons for variation in
performance across data samples are not fully understood.
Objectives: We investigate how differences in the measurement of
predictors across settings affect the discriminative power and trans-
portability of a prediction model.
Methods: Differences in predictor measurement between data sets can
be described formally using a “measurement error” taxonomy. Using
this taxonomy, we derive an expression relating variation in the meas-
urement of a continuous predictor to the area under the curve (AUC)
of a logistic regression prediction model. This expression is then used
to demonstrate how variation in measurements across samples affects
the out-of-sample discriminative ability of a prediction model. We illus-
trate these findings with a diagnostic model using example data of pa-
tients suspected of having deep vein thrombosis.
Results: When a predictor, such as D-dimer, is measured with more noise
in one setting compared to another, which we conceptualize as a differencein “classical measurement error”, the AUC decreases (Fig. 1a). In contrast,
constant, “structural”, error does not impact on the AUC of a logistic regres-
sion model, providing the magnitude of the error is the same among cases
and non-cases (Fig. 1b). As the differences in measurement methods (and
in turn differences in measurement error) become more complex, it be-
comes increasingly difficult to predict how the AUC will be affected.
Conclusion: When a prediction model is applied to a new sample, its dis-
criminative ability can change if the magnitude or structure of the meas-
urement error is not exchangeable between the two settings. This
provides an important starting point for researchers to better understand
how differences in measurement methods can affect the performance of a
prediction model when externally validating or implementing it in practice.O29
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Background: When designing a study to develop a new risk prediction
model, researchers should ensure their sample size is adequate in
terms of the number of participants (n) and events (E) relative to the
number of predictor parameters (p) considered for inclusion in the
model. Current sample size calculations are based on “rules of thumb”,
such as at least 10 events per predictor parameter (EPP), which receive
much debate and criticism.
Objectives: To produce a new sample size formula for studies develop-
ing a prediction model with either binary or time-to-event outcomes.
Specifically, to identify in advance of data collection, the sample size
needed to minimize the expected optimism in predictor effect estimates,
and thus the expected shrinkage required after model development.
Methods: We derive a closed-form sample size formula, based on utiliz-
ing the heuristic uniform shrinkage factor of Van Houwlingen and Le
Cessie. The formula allows researchers to identify n, p and EPP that cor-
respond to an expected shrinkage factor close to 1, such as 0.9, that re-
flects low overfitting. It requires researchers to pre-specify the
anticipated Cox-Snell R2 of the model, and we show how to identify
realistic values of R2 based on published information (e.g. C statistic) for
existing models in the same field. A suitable margin of error in other
relevant estimates (e.g. overall risks) is also recommended.
Results: We illustrate the approach using examples of diagnostic and
prognostic prediction models. This shows that, to target an expected
shrinkage factor of 0.9, a new diagnostic model for Chagas disease
requires an EPP of 3.9 and a new prognostic model for recurrent ven-
ous thromboembolism requires an EPP of 23.
Conclusion: Blanket rules of thumb for sample size are inappropriate,
and our alternative proposal allows sample size and EPP to be tai-
lored to the particular model and setting of interest.
Table 1 (abstract O31). Overview of the three approaches we distinguish
to assess the incremental value of a new predictor and the incremental
value of the D-dimer test for the prediction of deep venous thrombosis
Approach Research
question:
“What is the
incremental value
of a new
predictor...”
regression model
with and without
the new predictor
Modeling approach Incremental
value of D-
dimer test
(95%CI)
1. Existing
model
“...when the
original model is
used in the new
dataset as
originally
developed?”
α + β1lp (a)
vs.
α + β1lp + β2NP (b)
Refitting all
coefficients of the
model is not an
option. An
alternative is to
improve the
discrimination and
calibration of the
original model in
your dataset using
fractional
polynomials, splines
(‘), or simple
recalibration for the
linear predictor (lp)
of the original
model.
Note that α + β1 in
model (a) may differ
from α + β1 in
model (b) due to
adjustment for the
new predictor.
ΔAUC
NRIe
NRIc
0.085
(-0.012
to 0.18)
0.084
(0.013
to 0.15)
0.64
(0.56 to
0.72)
2. Model
revision
“...when the
original model is
optimally fit to
the new dataset?”
α + β1X1 + β2X2 (a)
vs.
α + β1X1 + β2X2 +
β3NP (b)
Refit entire model
with the same
predictors (a) and
add the new
predictor to a model
with the same
predictors as in the
original model (b).
Note that α + β1,2,3
in model (a) may
differ from α + β1,2,3
in model (b) due to
adjustment for the
new predictor.
ΔAUC
NRIe
NRIc
0.082
(-0.012
to 0.18)
0.083
(0.0074
to 0.16)
0.61
(0.52 to
0.70)
3. New
model
development*
“...when the new
predictor is
incorporated in
the original
model in the
new dataset?”
α + β1X1 + β3X3 (a)
vs.
α + β1X1 + β4NP (b)
Here β2X2 was
removed from the
existing model (a).
After adding the
new predictor (b)
β3X3 was replaced
by β4NP
Refit entire model
with the same
predictors, but now
allow predictor
selection (a). Repeat
this step, but now
after adding the
new predictor to the
list of candidate
predictors (b).
Note that model (b)
may include
different predictors
than model (a), due
to replacement of
predictors in model
(a) by the new
predictor in model
(b)
ΔAUC
NRIe
NRIc
0.080
(-0.015
to 0.17)
0.077
(0.0023
to 0.15)
0.59
(0.48 to
0.70)
α = intercept as estimated in the new dataset; βi = the association of predictor i with the
outcome in the new dataset; lp = the linear predictor by applying the existing model to
individuals in the new dataset; NP = the new predictor; AUC = Area Under the Receiver
Operating Characteristic; NRIe = net reclassification improvement (NRI), event-based: risk
categories: 0 – 15.9%, 15.9% – 100%; NRIc = net reclassification improvement (NRI), continuous
an “existing model” can be referred to as one that we don’t want to modify the coefficients of
because it is so well established in clinical practice. With “model revision” and “new model
development” we generally deal with a model that is open for modification and one that is not
established in clinical practice and for which the coefficients or even the included predictors
can be modified
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Background: We developed an R package diagmeta that implements
our model for meta-analysis of diagnostic test accuracy (DTA) studies
allowing for multiple cutoffs (Steinhauser 2016).
Objectives: To make this statistical method accessible to users with a
background in statistics, psychology, medicine, or public health.
Methods: The parametric model assumes that the values of the under-
lying biomarker follow two correlated distributions for individuals with/
without the target condition. Data can be entered either as study label,
cutoff, TP (true positive), TN (true negative), FP (false positive), FN (false
negative), or as individual participant data (study label, individual's meas-
urement, status). Users can choose between several mixed linear models
and specify the type of distribution (logistic or normal), and the weighting
method for studies (e.g., inverse variance weighting). For determination of
an optimal cutoff, weights for sensitivity and specificity can be specified.
Results: The output of diagmeta includes basic information such as the
number of studies and cutoffs, the empirical distribution of cutoffs, the op-
timal cutoff, sensitivity and specificity at this cutoff, and the area under the
summary ROC curve. For given cutoffs, pairs of sensitivity and specificity
with confidence intervals can be tabulated. If a prevalence is specified, pre-
dicted values are calculated. In addition, a flexible plot function is provided
to produce cumulative distribution plots, density plots, Youden index
curves, study-specific ROC curves, the summary ROC curve, and the sum-
mary operating point, optionally with a corresponding confidence region.
Conclusion: The R package diagmeta implements one of few available
statistical methods for meta-analysis of DTA studies with multiple cut-
offs and is now readily accessible. We plan to continuously extend and
update diagmeta, and possibly to include competing methods.
References:
Steinhauser S et al.: Modelling multiple thresholds in meta-analysis of
diagnostic test accuracy studies. BMC Med Res Methodol.
2016;16(1):97.doi:10.1186/s12874-016-0196-1.
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Background New predictors (e.g. biomarkers) are often assessed for
their incremental value on top of existing prediction models in a
new dataset, but methods to assess this incremental value differ, and
may actually answer different research questions.
Objectives To describe various approaches to assess the incremental
value of a new predictor and show that they differ in the research
questions they address, and the (magnitude of the) estimated incre-
mental value they identify.
Methods We distinguish three approaches: assessment of incremental
value with respect to 1) an existing model (“existing model”); 2) individual
predictors of an existing model (“model revision”); and 3) a selection of in-
dividual predictors which may be part of an existing model (“new model
development”). Using these three approaches we assessed the incremental
value of the D-dimer test to a deep venous thrombosis prediction model.
Results The approach influences the research question that is actually ad-
dressed and influences the (magnitude of the) estimated incremental
value (Table 1). The incremental value of the D-dimer test decreased with
increasing adjustments of the existing model to the new dataset. In the“existing model” approach, the misfit of the existing model in the new
dataset allows room for the apparent incremental value of a new predictor.
The “model revision” approach solves this and has been recommended as
the preferred way to assess the incremental value of a new predictor in a
new dataset. In the “new model development” approach, the primary
interest is not incremental value, but rather which combination of existing
predictors and a new predictor best predicts the outcome.
Conclusion We advise investigators in incremental value studies to
more explicitly consider using an approach that is in line with the re-
search question they aim to answer, and to be aware that the ap-
proach influences the incremental value that can be identified.
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Background
Biological variability (BV) studies measure the natural variability in test re-
sults occurring between and within individuals. BV estimates can guide ap-
propriate use of tests for monitoring and diagnosis. Analysis of these
studies routinely involves detecting and eliminating outliers. The risk of out-
lier removal inappropriately reducing estimates of variability is not known.
Objectives
To estimate the impact of commonly used methods to remove out-
liers in BV studies.
Methods
As biomarker data typically have a skewed distribution, measure-
ments yijkwere simulated following a log-normal distribution accord-
ing to the model ln(yijk) = ln(μ) + ln(αi) + ln(βij) + ln(εijk) where,
lnðαiÞ  Nð0; σ2GÞ , lnðβijÞ  Nð0; σ2I Þ , lnðεijkÞ  Nð0; σ2AÞ for pa-
tients i = 1, . . , 20, observations per patient j = 1, . . , 4 and assess-
ments per observation k = 1, 2. Analytical, within-individual and
between-individual standard deviations used were 0.5, 1 and 2 re-
spectively. We randomly introduced outliers mimicking missed digit
or laboratory errors, changing values by a factor of 10 or 2.
Outlier detection was performed using Cochran C test, Reed’s Criter-
ion, Tukey IQR rule, Dixon’s Q test, Grubb’s test and ±3SD. 5,000 sim-
ulations were run and results compared with the simulation
parameters.
Results
With outlier detection and removal used, in the absence of outliers,
analytical, within-individual and between-individual variability are
underestimated. Unnecessarily removal of measures varied between
methods; median(Q1,Q3)[min,max] removed for 5,000 simulations
using Cochran C test 2(0,4)[0,30] and Dixon’s Q test 0(0,0)[0,0].
Cochran C test and Tukey's IQR rule created the greatest bias ( −
10.6 × 10−4, −15.5 × 10−4 and −85.5 × 10−4 for analytical, within-
individual and between-individual standard deviations respectively).
There were differences in the ability of outlier detection methods
to detect real outliers dependent on the number present. Outliers
correctly identified and removed ranged from a median of 0% to
100%.
Conclusion
Identification of outliers in BV studies should lead to data checking
and correction where necessary. However, outlier detection methods
should be used as sensitivity analyses as they may lead to underesti-
mation of measures of variation.O33
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Binary logistic regression is one of the most frequently applied statis-
tical models for developing clinical prediction models. Developers of
such models often rely on an Events Per Variable criterion (EPV), not-
ably EPV ≥ 10, to determine the minimal sample size required and/or
the maximum number of candidate predictors that can be examined.
Objectives
To improve upon the existing sample size guidance for binary logis-
tic prediction models.
Methods
I present an extensive simulation study in which the influence
of: EPV, events fraction, number of candidate predictors, the cor-
relations and distributions of candidate predictor variables, area
under the ROC curve, and predictor effects on out-of-sample
predictive performance of prediction models were studied. The
out-of-sample performance (calibration, discrimination and prob-
ability prediction error) of developed prediction models was
evaluated before and after regression shrinkage and variable
selection.
Results
The results indicate that EPV fails to have a strong relation with
metrics of predictive performance, and is not an appropriate cri-
terion for (binary) prediction model development studies. Out-of-
sample predictive performance can better be approximated by
considering the number of predictors, the total sample size and
the events fraction.
Conclusion
Prediction modeling studies should not only consider EPV to deter-
mine sample size. Instead, new sample size criteria for prediction
models should be developed that take into account: the number of
candidate predictors, the total sample size and the events fraction. A
simple-to-apply formula for such sample size calculations is
presented.
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Background
In precision medicine, new biomarkers and genomic tests may con-
tribute to decision-making and improve outcomes by targeting ther-
apy who benefit most. There is discussion about the evidence base
required to make recommendations about their use. Do we need tri-
als, observational studies, models or a combination?
Objectives
To explore how evidence on the prognostic strength of a genomic
signature can contribute to individualized decision making on start-
ing adjuvant chemotherapy for women with breast cancer.
Methods
The MINDACT trial was a randomized trial that enrolled 6,693 women
with early-stage breast cancer. A 70-gene signature (Mammaprint)
was used to estimate genomic risk, and clinical risk was estimated by
a dichotomized version of the Adjuvant!Online risk calculator. 2,187
women with discordant risk results were randomly allocated to
chemotherapy or no chemotherapy. We simulated the full risk distri-
bution of these women and estimated individual benefit, assuming a
constant relative effect of chemotherapy.
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The trial showed a prognostic effect of the signature (adjusted
Hazard Ratio 2.4 for distant metastasis free survival, DMFS).
Chemotherapy led to a 1.5% higher 5-year DMFS in 1,550 women
(23%) with high clinical risk and low genomic risk. A decision-
analytic modeling approach showed wide variability in DMFS
within the high clinical risk group as defined in the trial, identi-
fied far fewer women who could benefit from genetic testing
(4% rather than 50%), and fewer candidates for chemotherapy
(3% rather than 27%). These proportions depended strongly on
the required minimum benefit from chemotherapy and the antici-
pated relative effect of chemotherapy.
Conclusions: A high-quality pragmatic trial may be insufficient to
directly inform clinical practice on the utility of a biomarker or
genomic test for individual women. This study illustrates that
more detailed risk estimation and further decision-analytic model-
ing may be required to support optimal clinical implementation.Fig. 1 (abstract O35). Classification plots showing sensitivity (true
positive rate, TPR) and false positive rate (FPR) by threshold for the
baseline model only (with 95% pointwise confidence intervals of TPR
and FPR for risk thresholds of 20%, 30%, 40% for risk of metastatic
remnants after chemotherapy in testicular cancer patients)
Fig. 2 (abstract O35). Classification plots including standardized
decision curve for the baseline and extended model combined, to
predict the risk of metastatic remnants after chemotherapy in
testicular cancer patientsO35
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Background:
Receiver operating characteristic (ROC) curves are widely used in re-
ports on clinical risk prediction models. Although the intent to dem-
onstrate the ability of a model to discriminate between patients with
and without a certain condition might be sincere, their presentation
and interpretation is often inadequate.
Objectives:
ROC curves yield an improvement over selective reporting at identi-
fied optimal thresholds in early stage studies. However, we argue
that most published ROC curves contain little useful information and
are used erroneously to evaluate clinical prediction models. At the
bare minimum classification thresholds should be displayed on the
ROC plots.
Methods:
We encourage the use of classification plots, which plot sensitiv-
ity and specificity separately by threshold. Such classification
plots can be supplemented with measures of clinical utility such
as net benefit. We illustrate the usefulness of classification plots
with a case study on residual mass diagnosis in metastatic tes-
ticular cancer patients.
Results:
ROC curves are common in the medical literature to evaluate the
performance of clinical prediction models. Our pragmatic search re-
vealed 62% of ROC curves were presented uninformatively. ROC
curves provide little information over and above the area under the
curve (AUC) as a summary of discriminatory ability when threshold
information is not plotted.
Conclusion:
We recommend to focus on the AUC, sensitivity and specificity at
clinically relevant thresholds, and, if a visualization of discriminatory
ability is desired, classification plots where sensitivity and specificity
is presented by threshold. Classification plots can be readily aug-
mented with standardized net benefit to assess the potential clinical
utility of a model.
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Background
Meta-analysis may produce estimates that are unrepresentative of a
test’s performance in practice. Tailored meta-analysis circumvents this
by deriving an applicable region for the practice and selecting the
studies compatible with the region. It requires the test positive rate, r
and prevalence, p being estimated for the setting but previous stud-
ies have assumed their independence.
Objective
The aim is to investigate the effects a correlation between test posi-
tive rate and prevalence has on estimating the applicable region and
how this affects tailored meta-analysis.
Method
Four methods for estimating 99% confidence intervals for r and
p were investigated: Wilson’s score, Clopper-Pearson’s exact
interval, the Bonferroni correction and Hotelling’s T2 statistic.
These were analysed in terms of the coverage probability using
simulation trials over different correlations, sample sizes, and
values for r and p. The methods were then applied to two pub-
lished meta-analyses with associated practice data and the ef-
fects on the applicable region, studies selected and summary
estimates evaluated.
Results
Hotelling’s T2 statistic with a continuity correction had the highest
median coverage (0.9971). This and the Clopper-Pearson method
with a Bonferroni correction both had coverage consistently above
0.99. The coverage of Hotelling’s T2 statistic intervals varied the least
across different correlations. For both meta-analyses, the number of
studies selected was largest when Hotelling’s T2 statistic was used to
derive the applicable region. In one instance this increased the sensi-
tivity by over 4% compared with tailored meta-analysis estimates
using other methods.Conclusion
Tailored meta-analysis returns estimates which are tailored to prac-
tice providing the applicable region is accurately defined. This is
most likely when the 99% confidence interval for test positive rate
and prevalence are estimated using Hotelling’s T2 statistic with a con-
tinuity correction. Potentially, the applicable region may be obtained
using routine electronic health data.
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Background: Breast cancer screening in Europe has been debated
heatedly in the last decades. The aim of this systematic review was
to quantify the impact of organized screening on breast cancer mor-
tality across European regions. To our knowledge, this review is the
first that comprised all available evidence from different types of
studies from all European regions and stringently used clearly de-
fined tools to appraise the quality of each study and thus summa-
rizes the best evidence.
Methods: Six databases were searched including Embase, Medline
and Web of Science from inception to April 2016. To identify all eli-
gible studies which showed the effect of organized screening on
breast cancer mortality, two reviewers independently applied prede-
fined inclusion and exclusion criteria regarding PICOS. Only original
studies in English with a minimum of five years of follow-up that
were either randomized controlled trials (RCTs) or observational stud-
ies were included. The Cochrane risk of bias instrument and the
Newcastle-Ottawa Scale were used to assess the risk of bias of the in-
cluded studies.
Results: Of the 3,336 references initially retrieved, 58 were included
in the final analysis. Those comprised 37 cohort studies, 14 case-
control studies and 7 randomized controlled trials. Surprisingly, none
were from Eastern Europe. The quality of the included studies was
very miscellaneous: only 14 were judged to be of very good or good
quality. Of those, the reduction in breast cancer mortality varied from
4% to 54% in Northern Europe, 45% to 51% in Southern Europe and
from 12% to 39% in Western Europe.
Conclusion: This systematic review provides evidence that organized
screening reduces mortality from breast cancer in all European re-
gions where screening was implemented and monitored, despite a
wide range of estimates. Quantification of the actual effects of
screening in terms of benefits is still lacking for Eastern Europe.Publisher’s Note
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